[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[PMC](#)[Taxonomy](#)[OMIM](#)[Bc](#)

Search

PubMed

for

Go

Clear

[Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)[About Entrez](#)

Display

Abstract

Show:

20

Sort

Send to

Text

[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Browser](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[LinkOut](#)[Cubby](#)[Related Resources](#)[Order Documents](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)[Privacy Policy](#)☐ 1: J Exp Med 1996 Mar 1;183(3):867-78[Related Articles, Links](#)


Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines.

Browning JL, Miatkowski K, Sizing I, Griffiths D, Zafari M, Benjamin CD, Meier W, Mackay F.

Department of Immunology and Inflammation, Biogen, Cambridge, Massachusetts 02142, USA.

Surface lymphotoxin (LT) is a heteromeric complex of LT-alpha and LT-beta chains that binds to the LT-beta receptor (LT-beta-R), a member of the tumor necrosis factor (TNF) family of receptors. The biological function of this receptor-ligand system is poorly characterized. Since signaling through other members of this receptor family can induce cell death, e.g., the TNF and Fas receptors, it is important to determine if similar signaling events can be communicated via the LT-beta-R. A soluble form of the surface complex was produced by coexpression of LT-alpha and a converted form of LT-beta wherein the normally type II LT-beta membrane protein was changed to a type I secreted form. Recombinant LT-alpha 1/beta 2 was cytotoxic to the human adenocarcinoma cell lines HT-29, WiDr, MDA-MB-468, and HT-3 when added with the synergizing agent interferon (IFN) gamma. When immobilized on a plastic surface, anti-LT-beta-R monoclonal antibodies (mAbs) induced the death of these cells, demonstrating direct signaling via the LT-beta-R. Anti-LT-beta-R mAbs were also identified that inhibited ligand-induced cell death, whereas others were found to potentiate the activity of the ligand when added in solution. The human WiDr adenocarcinoma line forms solid tumors in immunocompromised mice, and treatment with an anti-LT-beta-R antibody combined with human IFN-gamma arrested tumor growth. The delineation of a biological signaling event mediated by the LT-beta-R opens a window for further studies on its immunological role, and furthermore, activation of the LT-beta-R may have an application in tumor therapy.

PMID: 8642291 [PubMed - indexed for MEDLINE]



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search PubMed

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract

Show:

20

Sort

Send to

Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: J Immunol 1989 Sep 15;143(6):1859-67

Related Articles, Links

Studies on the differing effects of tumor necrosis factor and lymphotoxin on the growth of several human tumor lines.

Browning J, Ribolini A.

Department of Cell Biology and Immunology, Biogen Inc., Cambridge, MA 02142.

The relative ability of TNF and lymphotoxin (LT) to inhibit the growth of five human tumor cell lines was examined both in the presence and absence of IFN-gamma. Two adenocarcinoma lines, HT-29 and SK-CO-1, were 20- and 320-fold more sensitive to the inhibitory effects of TNF and LT in 3- to 4-day proliferation assays. In contrast, the breast carcinoma line BT-20 showed only a one- to twofold difference. The MCF-7 and ME-180 cell lines exhibited intermediate behavior. These results parallel the reported disparate potencies of TNF and LT in their effects on endothelial cells, hematopoietic development and their abilities to sustain a mixed lymphocyte response. Radiolabeled TNF binding studies showed two classes of receptors (Kd 0.04 to 0.15 nM and 0.2 to 1.0 nM) on the highly sensitive SK-CO-1 line. HT-29 cells also appeared to possess some high affinity-binding sites, whereas the BT-20 line completely lacked the high affinity form. Thus the presence of high affinity-binding sites correlated with increased sensitivity to the antiproliferative effects of TNF. Cold TNF competed with the binding of radiolabeled human TNF three- to fivefold better than LT for binding to all three lines. These relatively small differences between the TNF and LT receptor-binding characteristics are insufficient to explain the dramatic disparity in their antiproliferative properties. Likewise, the absolute concentrations of the unlabeled cytokines necessary to block the binding of 125I-TNF were 10- to 150-fold higher than the levels necessary to elicit the biologic response. Thus, the receptor binding data conflict with the growth inhibitory effects. This discrepancy is discussed in terms of either separate receptors for TNF and LT or more complex phenomena such as receptor cooperativity possibly resulting from multivalent interactions with the trimeric form of TNF.

PMID: 2550545 [PubMed - indexed for MEDLINE]

WEST**End of Result Set**☐ **Generate Collection** **Print**

L1: Entry 1 of 1

File: USPT

Jul 20, 1999

US-PAT-NO: 5925351

DOCUMENT-IDENTIFIER: US 5925351 A

TITLE: Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

DATE-ISSUED: July 20, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Browning; Jeffrey L.	Brookline	MA		
Benjamin; Christopher D.	Beverly	MA		
Hochman; Paula S.	Brookline	MA		


US-CL-CURRENT: 424/143.1; 424/144.1, 424/145.1, 424/156.1, 514/2, 514/8, 530/387.1, 530/388.22, 530/388.23, 530/388.73, 530/388.85, 530/389.2, 530/395

CLAIMS:

What is claimed is:

1. A method for altering a delayed type hypersensitivity response in an animal comprising the step of administering a pharmaceutical composition which comprises a therapeutically effective amount of a lymphotoxin -.beta. receptor blocking agent and a pharmaceutically acceptable carrier.
2. The method according to claim 1, wherein the lymphotoxin-.beta. receptor blocking agent is selected from the group consisting of a soluble lymphotoxin-.beta. receptor comprising a functional sequence of amino acids selected from the amino acids of SEQ.ID.NO.1, an antibody directed against lymphotoxin-.beta. receptor, and an antibody directed against a surface LT ligand comprising at least one lymphotoxin-.beta. subunit.
3. The method according to claim 2, wherein the animal is a mammal.
4. The method according to claim 3, wherein the mammal is a human.
5. The method according to claim 1, wherein the lymphotoxin-.beta.-receptor blocking agent comprises a soluble lymphotoxin-.beta. receptor comprising a functional sequence of amino acids selected from the amino acids of SEQ.ID.NO.1, and having a ligand binding domain that can bind to a surface LT ligand comprising at least one lymphotoxin-.beta. subunit.
6. The method according to claim 5, wherein the soluble lymphotoxin-.beta. receptor further comprises a human immunoglobulin Fc domain.
7. The method according to claim 1, wherein the LT-.beta.-R blocking agent comprises a monoclonal antibody directed against LT-.beta. receptor.
8. The method according to claim 7, wherein the composition is administered in an amount sufficient to coat LT-.beta. receptor-positive cells for 1 to 14 days.

9. The method according to claim 4, wherein the LT-.beta.-R blocking agent comprises anti-human LT-.beta.-R mAb BDA8 produced by the hybridoma cell line BD.A8.AB9 (ATCC Accession No: HB11798).
10. The method according to claim 1, wherein the LT-.beta.-R blocking agent comprises a monoclonal antibody directed against surface LT ligand.
11. The method according to claim 10, wherein the composition is administered in an amount sufficient to coat surface LT ligand-positive cells for 1 to 14 days.
12. The method according to claim 10, wherein the antibody is directed against a subunit of the LT ligand.
13. The method according to claim 4, wherein the LT-.beta.-R blocking agent comprises anti-human LT-.beta. mAb B9 produced by the hybridoma cell line B9.C9.1 (ATCC Accession No: 11962).
14. The method according to claim 3, wherein the mammal is a mouse and the LT-.beta.-R blocking agent comprises a monoclonal antibody directed against a murine surface LT ligand.
15. A method for treating inflammatory bowel disease in an animal comprising the step of administering a pharmaceutical composition which comprises a therapeutically effective amount of a lymphotoxin-.beta. receptor blocking agent and a pharmaceutically acceptable carrier.
16. The method according to claim 15 wherein the lymphotoxin-.beta. receptor blocking agent is selected from the group consisting of a soluble lymphotoxin-.beta. receptor comprising a functional sequence of amino acids selected from the amino acids of SEQ. ID.NO.1, an antibody directed against lymphotoxin .beta. receptor, and an antibody directed against a surface LT ligand comprising at least one lymphotoxin-.beta. subunit.



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search PubMed



for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract



Show:

20



Sort



Send to

Text



Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: J Immunol 1995 Jan 1;154(1):33-46

Related Articles, Links

Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.

Browning JL, Douglas I, Ngam-ek A, Bourdon PR, Ehrenfels BN, Miatkowski K, Zafari M, Yampaglia AM, Lawton P, Meier W, et al.

Department of Immunology and Inflammation, Biogen, Cambridge, MA 02142.

Lymphotoxin (LT) is a cytokine related to TNF, found in human systems in both secreted and membrane bound forms. The well characterized secreted form is a trimer of a single protein, LT-alpha, whereas the surface form is composed of a complex between two related molecules, LT-alpha and LT-beta. Because there is a distinct receptor for the complex, the membrane form is believed to signal via events different from those elicited by TNF and secreted LT-alpha. By using a battery of anti-LT-alpha and LT-beta mAbs, it is clear that two LT surface forms exist on the surface of PMA-activated II-23 cells, a human T cell hybridoma. Assuming that these surface forms are trimers, a minor form appears early after induction having an apparent stoichiometry of LT-alpha 2/beta 1 and is recognized by one group of anti-LT-alpha mAbs and the p55-TNF receptor. The second and predominant form has an apparent LT-alpha 1/beta 2 composition and is recognized by a second group of pan-tropic anti-LT-alpha mAbs and the LT-beta receptor. Neither of the heteromeric forms nor a putative LT-beta homotrimeric form were found to be secreted. The properties of surface LT on the II-23 cell system were similar to those of the surface LT forms on Chinese hamster ovary cells transfected with both LT-alpha and LT-beta genes and a number of lymphoid tumor lines. These experiments point toward the LT-alpha 1/beta 2 complex as the predominant membrane form of LT on the lymphocyte surface, and this complex is the primary ligand for the LT-beta receptor.

PMID: 7995952 [PubMed - indexed for MEDLINE]

Display

Abstract



Show:

20




Sort



Send to

Text



[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[PMC](#)[Taxonomy](#)[OMIM](#)[Bc](#)Search 

for

[Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)[About Entrez](#)

Show:



Sort

[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Browser](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[LinkOut](#)[Cubby](#)[Related Resources](#)[Order Documents](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)[Privacy Policy](#)☐ 1: J Immunol 1997 Oct 1;159(7):3299-310[Related Articles, Links](#)


Cytotoxic activities of recombinant soluble murine lymphotoxin-alpha and lymphotoxin-alpha beta complexes.

Mackay F, Bourdon PR, Griffiths DA, Lawton P, Zafari M, Sizing ID, Miatkowski K, Ngam-ek A, Benjamin CD, Hession C, Ambrose CM, Meier W, Browning JL.

Department of Immunology, Biogen, Cambridge, MA 02142, USA.

Human lymphotoxin-alpha (LT alpha) is found in a secreted form and on the surface of lymphocytes as a complex with a second related protein called lymphotoxin-beta (LT beta). Both secreted human LT alpha and TNF have similar biological activities mediated via the TNF receptors, whereas the cell surface LT alpha beta complex binds to a separate receptor called the LT beta receptor (LT beta R). The murine LT alpha and LT beta (mLT alpha and mLT beta) proteins have never been characterized. When recombinant mLT alpha was produced by either of several methods, the protein had a very low specific activity relative to that of human LT alpha in the conventional WEHI 164 cytotoxicity bioassay. The weak activity observed was inhibited by a soluble murine TNF-R55 Ig fusion protein (mTNF-R55-Ig), but not by mLT beta R-Ig. Coexpression of both mLT alpha and a soluble version of mLT beta in insect cells led to an LT alpha beta form that was cytotoxic in the WEHI 164 assay via the LT beta R. To determine whether natural mLT alpha-like forms with cytotoxic activity comparable to that of secreted human LT alpha were secreted from primary spleen cells, splenic lymphocytes were activated in various ways, and their supernatants were analyzed for cytotoxic activity. Using specific Abs to distinguish between mTNF and mLT, a TNF component was readily detected; however, there was no evidence for a secreted mLT alpha cytotoxic activity using this assay. Combined, these observations suggest that secreted mLT alpha may not play a role in the mouse via interactions with TNF-R55, and the ramifications of this hypothesis are discussed.

PMID: 9317128 [PubMed - indexed for MEDLINE]



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Show:

Sort

Send to

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: J Immunol 1997 Oct 1;159(7):3288-98

Related Articles, Links

Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes.

Browning JL, Sizing ID, Lawton P, Bourdon PR, Rennert PD, Majeau GR, Ambrose CM, Hession C, Miatkowski K, Griffiths DA, Ngam-ek A, Meier W, Benjamin CD, Hochman PS.

Department of Immunology, Biogen, Cambridge, MA 02142, USA.
Jeff_Browning@biogen.com

The lymphotoxin-alpha beta complex (LT alpha beta) is found on the surface of activated lymphocytes and binds to a specific receptor called the LT beta receptor (LT beta R). In the mouse, signaling through this pathway is important for lymph node development and splenic organization, yet the biochemical properties of murine LT alpha and LT beta are essentially unknown. Here we have used soluble receptor-Ig forms of LT beta R and TNF-R55 and mAbs specific for murine LT alpha, LT beta, and LT beta R to characterize the appearance of surface LT alpha beta complexes and LT beta R on several common murine cell lines. Cells that bound LT beta R also bound anti-LT alpha and anti-LT beta mAbs in a FACS analysis. The ability of these reagents to discriminate between surface TNF and LT was verified by analysis of surface TNF-positive, LPS-activated murine RAW 264.7 monocytic cells. Primary mouse leukocytes from spleen, thymus, lymph node, and peritoneum were activated in vitro, and CD4+ and CD8+ T cells as well as B cells expressed surface LT ligand but not the LT beta R. Conversely, elicited peritoneal monocytes/macrophages were surface LT negative yet LT beta R positive. This study shows that on mononuclear cells, surface LT complexes and receptor are expressed similarly in mice and man, and the tools described herein form the foundation for study of the functional roles of the LT system in the mouse.

PMID: 9317127 [PubMed - indexed for MEDLINE]

Display

Show:

Sort

Send to

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

i686-pc-linux-gnu Feb 4 2003 11:11:49

Display	Abstract	Show:	20	Sort	Send to	Text
---------	----------	-------	----	------	---------	------

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

i686-pc-linux-gnu Feb 4 2003 11:11:49

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:asapral642cxy

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 BELSTEIN: Reload and implementation of a New Subject Area
NEWS 4 ZDB will be removed from STN
NEWS 5 Apr 09 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.COM available in CAPUS, HCAPUS, and ZCAPUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 MEDLINE Reload
NEWS 11 PCTFUL has been reloaded
NEWS 12 FORESE no longer contains STANDARDS file segment
NEWS 13 USAN to be reloaded July 28, 2002;
NEWS 14 saved answer sets no longer valid
NEWS 15 Enhanced polymer searching in REGISTRY
NEWS 16 NETFIRST to be removed from STN
NEWS 17 PHARMARET (PHARMARET) - new on STN
NEWS 18 NRTS has been reloaded and enhanced
NEWS 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPLO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 CA Section Thesaurus available in CAPUS and CA
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27 Oct 21 EVENTLINE has been reloaded
NEWS 28 Oct 24 BELSTEIN adds new search fields
NEWS 29 Nutraceuticals International (NUTRACUT) now available on STN
NEWS 30 MEDLINE SDI run of October 8, 2002
NEWS 31 DKILIT has been renamed APOILIT
NEWS 32 Nov 18 More calculated properties added to REGISTRY
NEWS 33 Dec 02 TIBKAT will be removed from STN
NEWS 34 Dec 04 CSA files on STN
NEWS 35 PCTFUL now covers WP/PCT Applications from 1978 to date
NEWS 36 Dec 17 TOXCENTER enhanced with additional content
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 38 ISMEC no longer available
NEWS 39 Indexing added to some pre-1967 records in CA/CAPUS
NEWS 40 NUTRACUT offering one free connect hour in February 2003
NEWS 41 PHARMATL offering one free connect hour in February 2003
NEWS 42 Simultaneous left and right truncation added to COMPENDEX,
ENERGY, INSPEC
NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0ub(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 12:32:53 ON 11 FEB 2003

=> file medline, cancerlit, biosis, confsci, embase, caplus, uspatfull
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 12:33:20 ON 11 FEB 2003

FILE 'CANCERLIT' ENTERED AT 12:33:20 ON 11 FEB 2003

FILE 'BIOSIS' ENTERED AT 12:33:20 ON 11 FEB 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CONFSCI' ENTERED AT 12:33:20 ON 11 FEB 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'EMBASE' ENTERED AT 12:33:20 ON 11 FEB 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 12:33:20 ON 11 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:33:20 ON 11 FEB 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 'lymphotoxin (a) beta (a) receptor and antibody'
5 FILES SEARCHED...
136 LYMPHOTOXIN (A) BETA (A) RECEPTOR AND ANTIBODY?

=> s '11 and interferon'
42 11 AND INTERFERON?

=> dup rem 12
PROCESSING COMPLETED FOR L2
L3 34 DUP REM L2 (8 DUPLICATES REMOVED)

=> d 1-34

L3 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1
AN 2002:409195 CAPLUS
DN 137:1567
TI Human apoptosis inducing molecule II and its cDNA and use thereof in drug

IC [7]
 ICM: C12P021-02
 ICS: C12N005-06; C07H021-04; C12N009-12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 34 USPATFULL
 AN 2002:272468 USPATFULL
 TI Tumor necrosis factor receptors 6alpha & 6beta
 IN Gentz, Reinhard, Galthersburg, MD, UNITED STATES
 Ebnert, Reinhard, Galthersburg, MD, UNITED STATES
 Yu, Guo-liang, Berkeley, CA, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Ni, Jian, Germantown, MD, UNITED STATES
 Peng, Ping, Galthersburg, MD, UNITED STATES
 Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

PI US 2002:150583 AI 2002:1017
 AI US 2001:935727 AI 2001:0824 (9)
 RLI Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING

PRAI US 2001:303224P 2001:0706 (60)
 US 2000-252131P 2000:1121 (60)
 US 2000-227598P 2000:0825 (60)
 US 1999-168235P 1999:1201 (60)
 US 1999-146371P 1999:0802 (60)
 US 1999-131964P 1999:0430 (60)
 US 1999-131270P 1999:0427 (60)
 US 1999-124092P 1999:0312 (60)
 RLI US 1999-121774P 1999:0304 (60)
 US 1997-35496P 1997:0114 (60)

DT Utility
 FS Application

IN.CNT 12989
 INCL INCLM: 424/178.100
 INCL: 530/388.100
 NCLM: 424/178.100
 NCL: 530/388.100

IC [7]
 ICM: A61K039-395
 ICS: C07K016-46
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 34 USPATFULL
 AN 2002:259408 USPATFULL
 TI Gene expression profiles in liver cancer
 IN Horne, Darci T., Galthersburg, MD, UNITED STATES
 Scherf, Uwe, Galthersburg, MD, UNITED STATES
 Vockley, Joseph, Damascus, MD, UNITED STATES
 PI US 2002:142981 AI 2002:1003
 AI US 2001-880107 AI 2001:0614 (9)
 PRAI US 2000-211379P 2000:0614 (60)
 US 2000-237054P 2000:1002 (60)

DT Utility
 FS Application

IN.CNT 15937
 INCL INCLM: 514/044.000
 INCL: 435/006.000
 NCLM: 514/044.000
 NCL: 435/006.000

IC [7]
 ICM: A61K048-00
 ICS: C12P001-68
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 34 USPATFULL
 AN 2002:235448 USPATFULL
 TI Human tumor necrosis factor receptor-like protein 8
 IN Ni, Jian, Rockville, MD, UNITED STATES
 Moore, Paul A., Germantown, MD, UNITED STATES
 PI US 2002:127637 AI 2002:0912
 AI US 2001-768779 AI 2001:0125 (9)
 RLI Continuation of Ser. No. US 1998-66582, filed on 29 May 1998, ABANDONED
 PRAI US 1997-48020P 1997:0529 (60)

DT Utility
 FS Application

IN.CNT 3660
 INCL INCLM: 435/069.100
 INCL: 435/320.100; 435/325.000; 530/350.000; 536/023.500
 NCLM: 435/069.100
 NCL: 435/320.100; 435/325.000; 530/350.000; 536/023.500

IC [7]
 ICM: C07K014-715
 ICS: C12P021-02; C12N005-06; C07H021-04
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 34 USPATFULL
 AN 2002:235426 USPATFULL
 TI TRAF-3 deletion isoforms and uses thereof
 IN Lederman, Seth, New York, NY, UNITED STATES
 Eynhove, Winfried Van, Bellport, NY, UNITED STATES
 PI US 2002:127615 AI 2002:0912
 AI US 2001-950902 AI 2001:0910 (9)
 RLI Continuation of Ser. No. US 2000-056503, filed on 10 Mar 2000, UNKNOWN
 PENDING Continuation-in-part of Ser. No. US 1999-268544, filed on 11 Mar 1999,

DT Utility
 FS Application

IN.CNT 4140
 INCL INCLM: 435/007.210
 INCL: 435/183.000; 435/325.000; 435/320.100; 530/350.000; 536/023.200
 NCLM: 435/007.210
 NCL: 435/183.000; 435/325.000; 435/320.100; 530/350.000; 536/023.200

IC [7]
 ICM: G01N033-567
 ICS: C07H021-04; C12N009-00; C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 34 USPATFULL
 AN 2002:206139 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of colon cancer
 IN Pyle, Ruth A., Seattle, WA, UNITED STATES
 Xu, Jiangchun, Bellevue, WA, UNITED STATES
 Secrist, Heather, Seattle, WA, UNITED STATES
 Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
 PI US 2002:110832 AI 2002:0815
 AI US 2001-919580 AI 2001:0730 (9)
 PRAI US 2001-302702P 2001:0703 (60)
 US 2001-277495P 2001:0320 (60)
 US 2000-237406P 2000:1002 (60)
 US 2000-223265P 2000:0803 (60)

DT Utility
 FS Application

IN.CNT 5425
 INCL INCLM: 435/007.100
 INCL: 536/023.100; 530/350.000
 NCLM: 435/007.100
 NCL: 536/023.100; 530/350.000

IC [7]

ICM: G01N033-53
ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 34 USPATFULL
AN 2002:171619 USPATFULL
TI Anti-lymphotoxin-beta receptor
IN Antibodies as anti-tumor agents
Browning, Jeffrey L., Brookline, MA, UNITED STATES
Meier, Werner, Burlington, MA, UNITED STATES
Benjamin, Christopher D., Beverly, MA, UNITED STATES
PI US 2002090366 A1 20020711
AI US 2001-933402 A1 20010816 (9)
RLI Division of Ser. No. US 1998-875560, filed on 5 Jun 1998, PATENTED A 371
of International Ser. No. WO 1996-US1386, filed on 26 Jan 1996, UNKNOWN
Continuation-in-part of Ser. No. US 1995-378968, filed on 26 Jan 1995.
PENDING

DT Utility
FS APPLICATION
LN.CNT 1764
INCL INCLM: 424/094.100
NCL INCLM: 424/178.100
NCLM: 424/094.100
IC NCLS: 424/178.100
[7]
ICM: A61K039-395
ICS: A61K039-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 34 USPATFULL
AN 2002:157048 USPATFULL
TI APOPTOSIS INDUCING MOLECULE 11 AND METHODS OF USE
EBNER, REINHARD, GAITHERSBURG, MD, UNITED STATES
YU, GUO-LIANG, BERKELEY, CA, UNITED STATES
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES
ZHANG, JUN, BETHESDA, MD, UNITED STATES
ULRICH, STEPHEN, ROCKVILLE, MD, UNITED STATES
ZHA1 YIPAN, GAITHERSBURG, MD, UNITED STATES
PA Human Genome Sciences (U.S. corporation)
PI US 2002081647 A1 20020627
B2 20021217
AI US 6495520 A1 19990219 (9)
RLI Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998,
PENDING Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan
1998, ABANDONED Continuation-in-part of Ser. No. US 1997-822953, filed
on 21 Mar 1997, ABANDONED
PRAI US 1998-75409P 19980220 (60)
US 1996-13923P 19960322 (60)
US 1996-30157P 19961031 (60)
DT Utility
FS APPLICATION
LN.CNT 6195
INCL INCLM: 435/069.100
NCL INCLM: 530/350.000; 530/399.000; 514/012.000; 536/023.500
NCLM: 514/012.000
IC NCLS: 530/300.000; 530/324.000; 530/350.000
[7]
ICM: A61K038-18
ICS: C12P021-06; C07H021-04; C07K014-00; G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 34 USPATFULL
AN 2002:119846 USPATFULL
TI Human G-protein Chemokine receptor (CCRS) HDGNR10
IN Rosen, Craig A., Laytonville, MD, UNITED STATES

PI Roschke, Viktor, Rockville, MD, UNITED STATES
AI Yi, Sunnyvale, CA, UNITED STATES
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES
PRAI US 2002061834 A1 20020523
AI US 2001-779880 A1 20010209 (9)
US 2000-18128P 20000209 (60)
US 2000-187999P 20000309 (60)
US 2000-234336P 20000922 (60)
DT Utility
FS APPLICATION
LN.CNT 18667
INCL INCLM: 514/001.000
NCL INCLM: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100
NCLM: 514/001.000
IC NCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100
[7]
ICM: A61K031-00
ICS: C07H021-04; C07K014-05; C12N005-06; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 34 USPATFULL
AN 2002:92268 USPATFULL
TI Human G-protein Chemokine Receptor HDGNR10
IN Rosen, Craig A., Laytonville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
LI, Yi, Sunnyvale, CA, UNITED STATES
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES
PI US 2002048786 A1 20020425
AI US 2001-779879 A1 20010209 (9)
PRAI US 2000-181258P 20000209 (60)
US 2000-187999P 20000309 (60)
US 2000-234336P 20000922 (60)
DT Utility
FS APPLICATION
LN.CNT 17969
INCL INCLM: 435/069.100
NCL INCLM: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000
NCLM: 435/069.100
IC NCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000
[7]
ICM: G01N033-53
ICS: G01N033-567; A61K038-00; C07H021-04; C12P021-06; A61K039-395;
C12N005-02; C12N005-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 34 USPATFULL
AN 2002:67215 USPATFULL
TI Method for detecting hepatitis C
IN Budkowska, Agata, Clamart, FRANCE
Mailard, Patrick, Clamart, FRANCE
Bromert, Christian, Fresnes, FRANCE
Gounon, Pierre, Noisieu, FRANCE
Nikiewicz, Jadwiga, Komorow, POLAND
Grainic, Radu, Joux En Joaze, FRANCE
PI INSTITUT PASTEUR, Paris Cedex, FRANCE
AI US 2002037868 A1 20020328
PRAI US 2001-80945 A1 20010615 (9)
US 2000-234336P 20000922 (60)
DT Utility
FS APPLICATION
LN.CNT 1656
INCL INCLM: 514/044.000
INCLM: 435/005.000; 435/007.950; 435/091.330; 435/975.000

NCL NCLM: 514/044.000
NCLS: 435/005.000; 435/007.950; 435/091.330; 435/975.000
IC [7]

ICM: C120001-70
ICS: G01N033-53; G01N033-543; A61K031-70; A01N043-04;
C12P019-34

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 34 USPTAFULL
AN 2002:26858 USPTAFULL
TI Antagonists of tweak and of tweak receptor and their use to treat
immunological disorders
IN Remmert, Paul, Miller, MA, UNITED STATES
PI US 2002015703 A1 20020207
AI US 2001-905810 A1 20010713 (9)
PRAI WO 2000-US1044 20000114
DT US 1999-116168P 19990115 (60)
FS APPLICATION
LN.CNT 1303
INCL INCLM: 424/143.100
NCL NCLM: 424/143.100
IC [7]

ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 34 USPTAFULL
AN 2002:22092 USPTAFULL
TI Nucleic acid sequences associated with aging, particularly skin aging
IN Burnet, Glenna C., Seattle, WA, UNITED STATES
PI US 2002012927 A1 20020131
AI US 2001-802718 A1 20010308 (9)
PRAI US 2000-188584P 20000310 (60)
DT Utility
FS APPLICATION
LN.CNT 2368
INCL INCLM: 435/006.000
NCL NCLM: 435/007.210
NCLM: 435/006.000
NCLS: 435/007.210
IC [7]

ICM: C120001-68
ICS: G01N033-567; A61K031-665
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 17 OF 34 USPTAFULL
AN 2002:8587 USPTAFULL
TI Multivalent antibodies and uses therefor
IN Miller, Kathy L., San Francisco, CA, UNITED STATES
PI Presta, Leonard G., San Francisco, CA, UNITED STATES
GENENTECH, INC. (U.S. corporation)
PI US 2002004587 A1 20020110
AI US 2001-813341 A1 20010320 (9)
PRAI US 2000-195819P 20000411 (60)
DT Utility
FS APPLICATION
LN.CNT 4913
INCL INCLM: 530/388.800
NCL NCLM: 536/023.500; 435/325.000; 435/334.000; 424/143.100
NCLS: 536/023.500; 435/325.000; 435/334.000; 424/143.100
IC [7]

ICM: C07K016-28

ICS: A61K039-395; C07H021-04; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 18 OF 34 USPTAFULL
AN 2002:13612 USPTAFULL
TI Reversal of viral-induced systemic shock and respiratory distress by
blockade of the lymphotoxin beta pathway
IN Browning, Jeffrey, Brookline, MA, UNITED STATES
PI Pugliese, Maryann, Alexandria, VA, UNITED STATES
PI US 2002001585 A1 20020103
AI US 2001-829031 A1 20010409 (9)
PRAI US 1998-103662P 19981009 (60)
DT Continuation of Ser. No. WO 1999-US23477, filed on 8 Oct 1999, UNKNOWN
FS Utility
LN.CNT 1040
INCL INCLM: 424/143.100
NCL INCLM: 424/147.100; 435/328.000; 435/334.000
NCLM: 424/143.100
NCLS: 424/147.100; 435/328.000; 435/334.000
IC [7]

ICM: A61K039-42
ICS: A61K039-395; C12N005-06; C12N005-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 19 OF 34 USPTAFULL
AN 2002:152777 USPTAFULL
TI Nucleic acid encoding a TRAF-3 deletion isoform
IN Lederman, Seth, New York, NY, United States
PI Van Eynhoven, Wintfried, Bayside, NY, United States
The Trustees of the University in the City of New York, New York, NY,
United States (U.S. corporation)
PI US 6410710 B1 20020625
AI US 1999-268544 19990311 (9)
DT Utility
FS GRANTED

LN.CNT 3011
INCL INCLM: 536/023.500
NCL INCLM: 536/023.100; 435/320.100
NCLM: 536/023.500
NCLS: 435/320.100; 536/023.100
IC [7]

ICM: C07H021-04
ICS: C12N015-11; C12N015-63
EXF 536/23.1; 536/23.5; 435/320.1; 424/93.1; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 20 OF 34 USPTAFULL
AN 2002:136562 USPTAFULL
TI Soluble lymphotoxin-beta receptors as
therapeutic agents for the treatment of immunological disease
IN Browning, Jeffrey L., Brookline, MA, United States
Benjamin, Christopher D., Beverly, MA, United States
Hochman, Paula S., Newton, MA, United States
Biosgen, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6403087 B1 20020611
AI WO 9703687 19970206
WO 1996-US12010 19980608 (9)
US 1998-166 19960719
PCT 371 date
Continuation-in-part of Ser. No. US 1995-505606, filed on 21 Jul 1995,
now patented, Pat. No. US 5925351
DT Utility
FS GRANTED

LN CNT 1983
INCL INCLM: 424/134.100
INCLM: 424/134.100; 424/133.100; 514/002.000; 514/008.000; 530/387.100;
530/387.300
NCLM: 424/134.100
NCLM: 424/133.100; 514/002.000; 514/008.000; 530/387.100; 530/387.300
IC [7]
ICM: A61K039-395
EXF ICS: A61K038-16
424/148.1; 424/144.1; 424/145.1; 424/156.1; 514/2; 514/8; 530/395;
530/387.1; 530/388.22; 530/388.23; 530/388.73; 530/388.85; 530/389.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L3 ANSWER 21 OF 34 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2002:419176 BIOSIS
DN PREV200200419176
TI Lymphotoxin-beta receptor agonist monoclonal
AU antibodies have antitumor properties.
Lepage, Doreen J. (1); Wilson, C. A.; Gardner, E.; Bailey, V.; Ngam-Ek, A.;
Dirig, J.; Jarpe, M.; Lukashew, M.; Xu, X.; Szelliga, K.; Kelly, R.; Fawell,
S.; Tao, N.; Boral, A.; Myers, J.; Browning, J.
CS (1) Biogen, Inc., Cambridge, MA USA
SO Proceedings of the American Association for Cancer Research Annual
Meeting, (March, 2002) Vol. 43, pp. 1005. Print.
Meeting Info.: 93rd Annual Meeting of the American Association for Cancer
Research San Francisco, California, USA April 06-10, 2002
ISSN: 0197-016X.
DT Conference
LA English
L3 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2003 ACS
AN 2001:904598 CAPLUS
DN 136:2535
TI Compositions, kits, and methods for identification and modulation of type
I diabetes
IN Byrne, Michael C.; Hill, Andrew A.; Wilson, S. Brian
PA Genetics Institute, Inc., USA; General Hospital Corporation
SO PCT Int. Appl., 123 pp.
CODEN: PIXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2001094636 A2 20011213 WO 2001-US18418 20010605
W: AE, AG, AU, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NL, NO,
NU, OV, PA, PE, PG, PH, PK, PL, PT, RU, RW, SD, SE, SG, SI, SK, SL,
SM, SN, SR, ST, SV, SZ, TD, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZM, ZW, AM, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NI, SN, TD, TG
US 2002039736 A1 20020404 US 2001-875451 20010605
PRAI US 2000-209703P P 20000605
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

PA National Science Council, Taiwan
SO Taiwan, 5 pp.
CODEN: TWXMA5
DT Patent
LA Chinese
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI TW 434316 B 20010516
PRAI TW 1998-87113614 19980819
L3 ANSWER 24 OF 34 USPTFULL
AN 2001:231143 USPTFULL
TI Arrays for identifying agents which mimic or inhibit the activity of
interferons
IN Silverman, Robert H.; Beachwood, OH, United States
Williams, Bryan R. G., Cleveland, OH, United States
Der, Sandy, Cleveland, OH, United States
The Cleveland Clinic Foundation, Cleveland, OH, United States (U.S.
corporation)
PA US 6311396 B1 20011218
AI US 1999-405438 19990923 (9)
PRAI US 1998-101497P 19980923 (60)
DT Utility
FS GRANTED
LN.CNT 9639
INCL INCLM: 435/006.000
INCLM: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
NCLM: 435/006.000
NCLM: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
IC [7]
ICM: C120001-68
EXF ICS: C12M001-36; C07H021-04
435/6; 435/287.2; 536/23.1; 536/24.31; 536/23.52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L3 ANSWER 25 OF 34 USPTFULL
AN 2001:196600 USPTFULL
TI Lymphotoxin-.alpha.-.beta. complexes and anti-lymphotoxin-.beta. receptor
antibodies as anti-tumor agents
IN Browning, Jeffrey L., 32 Milton Rd., Brookline, MA, United States 02146
Meier, Werner, 31 Bedford St., Burlington, MA, United States 01803
Benjamin, Christopher D., 2 Oak Hill La., Beverly, MA, United States
01915
PI US 6312691 B1 20011106
AI WO 9622788 19960801
US 1998-875560 19980605 (8)
WO 1996-US1386 19960126 19980605 PCT 371 date
19980605 PCT 102(e) date
DT Utility
FS GRANTED
LN.CNT 2254
INCL INCLM: 424/143.100
INCLM: 424/130.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;
530/388.750; 530/388.800; 530/388.850
NCLM: 424/143.100
NCLM: 424/130.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;
530/388.750; 530/388.800; 530/388.850
IC [7]
ICM: A61K039-395
EXF ICS: A61K038-16
424/130.1; 424/143.1; 424/144.1; 424/809; 530/388.22; 530/388.7;
530/388.75; 530/388.8; 530/388.85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 26 OF 34 USPATFULL
AN 2001:75530 USPATFULL
TI Fas ligand-like protein, its production and use
IN Nishi, Kazunori, Ibaraki, Japan
Hikichi, Yukiko, Ibaraki, Japan
Shitani, Yasushi, Ibaraki, Japan
Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PA US 6235878 B1 20010522
PI WO 9803648 19980129
AI WO 1997-913014 19970904 (8)
MO 1997-JP2480 19970717
19970904 PCT 371 date
19970904 PCT 102(e) date
JP 1996-191204 19960719
JP 1996-211695 19960809
JP 1997-19330 19970131
DT Utility
FS Granted
LN CNT 4854
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC (7)
ICM: C07K001-00
EXF 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 27 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 2001104651 EMBASE
TI Peyer's patches are required for oral tolerance to proteins.
AU Fujinashi K.; Dohi T.; Remnert P.D.; Yamamoto M.; Koga T.; Kiyono H.;
McChee J.R.
CS K. Fujinashi, Department of Oral Biology, Immunobiology Vaccine Center,
University of Alabama, BBRB 761, Birmingham, AL 35294-2170, United States.
kohtaro@uab.edu
SO Proceedings of the National Academy of Sciences of the United States of
America. (13 Mar 2001) 98/6 (3310-3315).
Refs: 44
ISSN: 0027-8424 CODEN: PNASA6
CY United States
FS Journal; Article
LA English
SL English

L3 ANSWER 28 OF 34 MEDLINE
AN 2001481745 MEDLINE
DN 21400854 PubMed ID: 11509623
TI Elimination of colonic patches with lymphotoxin beta
AU Dohi T.; Remnert P.D.; Fujinashi K.; Kiyono H.; Shirai Y.; Kawamura Y I;
Browning J L; McGhee J R
CS Department of Gastroenterology, Research Institute, International Medical
Center of Japan, Tokyo, Japan.. dohi@ri.imcj.go.jp
NC A118958 (NIAID)
A135932 (NIAID)
A143197 (NIDCR)
DE09837 (NIDCR)
DE12242 (NIDCR)
DK44240 (NIDCR)
F30DKS4781 (NIDDK)
SO JOURNAL OF IMMUNOLOGY, (2001 Sep 1) 167 (5) 2781-90.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English

FS Abridged Index Medicus Journals; Priority Journals
EM 200112
ED Entered STM: 20010830
Last Updated on STM: 20020122
Entered Medline: 20011205

L3 ANSWER 29 OF 34 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. DUPLICATE
AN 2001:278934 BIOSIS
DN PREV200100278934
TI Recombinant, soluble LIGHT (HVEM ligand) induces increased IL-8 secretion
and growth arrest in A375 melanoma cells.
AU Hehlhans, Thomas; Maennel, Daniela N. (1)
CS (1) Institute of Pathology/Tumor Immunology, University of Regensburg,
F.-J.-Strauss-Allee 11, D-93042, Regensburg; daniela.maennel@klinik.uni-
regensburg.de Germany
SO Journal of Interferon and Cytokine Research, (May, 2001) Vol. 21, No. 5,
pp. 333-338. Print.
ISSN: 1079-9907.
DT Article
LA English
SL English

L3 ANSWER 30 OF 34 USPATFULL
AN 2000:146513 USPATFULL
TI Ligand for herpes simplex virus entry mediator and methods of use
IN Ware, Carl E.; Solana Beach, CA, United States
PA La Jolla Institute for Allergy and Immunology, La Jolla, CA, United
States (U.S. corporation) 20001031
PI US 6140467 19970730 (8)
AI US 1997-898234 19970707 (60)
PRAI US 1997-51964P
DT Utility
FS Granted
LN CNT 1522
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC (7)
ICM: C07K014-47
EXF 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 31 OF 34 MEDLINE
AN 2000219245 MEDLINE
DN 20019245 PubMed ID: 10754304
TI LIGHT, a TNF-like molecule, costimulates T cell proliferation and is
required for dendritic cell-mediated allogeneic T cell response.
AU Tamada K.; Shimozaki K.; Chapoval A I; Zhai Y; Su J; Chen S F; Hsieh S L;
Nagata S; Ni J; Chen L
CS Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic,
Rochester, MN 55905, USA.
SO JOURNAL OF IMMUNOLOGY, (2000 Apr 15) 164 (8) 4105-10.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200005
ED Entered STM: 20000518
Last Updated on STM: 20000518
Entered Medline: 20000509

L3 ANSWER 32 OF 34 USPATFULL
AN 1999:81563 USPATFULL
TI Soluble lymphotoxin-beta. receptors and

ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 43 USPTAFULL
AN 2002:272856 USPTAFULL
TI TNF receptor-like molecules and uses thereof
IN Theill, Lars Eyde, Thousand Oaks, CA, UNITED STATES
Yen, Richard, Ithaca, NY, UNITED STATES
Silbiger, Scott Michael, Woodland Hills, CA, UNITED STATES
Yu, Gang, Thousand Oaks, CA, UNITED STATES
Senaldi, Giorgio, Thousand Oaks, CA, UNITED STATES

PI US 2002150977 AI 20021017
AI US 2001-948018 AI 20010905 (9)
PRAI US 2000-230191P 20000905 (60)
DT Utility
FS APPLICATION

IN.CMT 5781
INCL INCLM: 435/069.100
INCLS: 435/325.000; 435/320.100; 530/350.000; 536/023.500; 435/194.000
NCLM: 435/069.100
NCLS: 435/325.000; 435/320.100; 530/350.000; 536/023.500; 435/194.000

IC [7]
ICM: C12P021-02
ICS: C12N005-06; C07H021-04; C12N009-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 43 USPTAFULL
AN 2002:272468 USPTAFULL

TI Tumor necrosis factor receptors α 1 and β 2
IN Gentz, Reiner L., Rockville, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Yu, Guo-liang, Berkeley, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Feng, Ping, Gaithersburg, MD, UNITED STATES
Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. Corporation)

PI US 2002150583 AI 20021017
AI US 2001-935727 AI 20010824 (9)
R1 Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING

PRAI US 2001-303224P 20010706 (60)
US 2000-252131P 20001121 (60)
US 2000-227598P 20000825 (60)
US 1999-168235P 19991201 (60)
US 1999-146371P 19990802 (60)
US 1999-131964P 19990430 (60)
US 1999-131270P 19990427 (60)
US 1999-124092P 19990312 (60)
US 1999-121774P 19990304 (60)
US 1997-35496P 19970114 (60)

DT Utility
FS APPLICATION
IN.CMT 12989
INCL INCLM: 424/178.100
INCLS: 530/389.100
NCLM: 424/178.100
NCLS: 530/389.100

IC [7]
ICM: A61K039-395
ICS: C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 43 USPTAFULL
AN 2002:259408 USPTAFULL

TI Gene expression profiles in liver cancer
IN Horne, Darci T., Gaithersburg, MD, UNITED STATES
Scherf, Uwe, Gaithersburg, MD, UNITED STATES
Vockley, Joseph, Damascus, MD, UNITED STATES

PI US 2002142981 AI 20021003
AI US 2001-880107 AI 20010614 (9)
PRAI US 2000-211379P 20000614 (60)
US 2000-237054P 20001002 (60)
DT Utility
FS APPLICATION

IN.CMT 15937
INCL INCLM: 514/044.000
INCLS: 435/006.000
NCLM: 514/044.000
NCLS: 435/006.000

IC [7]
ICM: A61K048-00
ICS: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 43 USPTAFULL
AN 2002:235448 USPTAFULL

TI Human tumor necrosis factor receptor-like protein 8
IN Ni, Jian, Rockville, MD, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
PI US 2002127637 AI 20020912
AI US 2001-768779 AI 20010125 (9)
R1 Continuation of Ser. No. US 1998-86582, filed on 29 May 1998, ABANDONED
PRAI US 1997-48020P 19970529 (60)
DT Utility
FS APPLICATION

IN.CMT 3860
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500

IC [7]
ICM: C07K014-715
ICS: C12P021-02; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 43 USPTAFULL
AN 2002:235426 USPTAFULL

TI TRAF-3 deletion isoforms and uses thereof
IN Lederman, Seth, New York, NY, UNITED STATES
Eynhove, Winfried Van, Bellport, NY, UNITED STATES
PI US 2002127615 AI 20020912
AI US 2001-950902 AI 20010910 (9)
R1 Continuation of Ser. No. US 2000-056503, filed on 10 Mar 2000, UNKNOWN
PRAI US 1999-268544, filed on 11 Mar 1999, PENDING

DT Utility
FS APPLICATION
IN.CMT 4140
INCL INCLM: 435/007.210
INCLS: 435/183.000; 435/325.000; 435/320.100; 530/350.000; 536/023.200
NCLM: 435/007.210
NCLS: 435/183.000; 435/325.000; 435/320.100; 530/350.000; 536/023.200

IC [7]
ICM: G01N033-567
ICS: C07H021-04; C12N009-00; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 43 USPATFULL
AN 2002:228312 USPATFULL
TI Treatment of autoimmune disease
IN Faustman, Denise, Weston, MA, UNITED STATES
PI US 2002:234722 A1 20020905
RI US 2001-768769 A1 20010123 (9)
R11 Continuation-in-part of Ser. No. US 2000-521064, filed on 8 Mar 2000,
ABANDONED
PRAI US 1999-123738P 19990310 (60)
DT Utility
FS APPLICATION
LN.CNT 1830
INCL INCLM: 514/044.000
NCLM: 435/005.000; 435/235.100; 435/325.000; 435/007.920; 435/069.500
NCLM: 514/044.000
NCLM: 435/005.000; 435/235.100; 435/325.000; 435/007.920; 435/069.500
IC [7]
ICM: C12Q001-70
ICS: G01N033-53; G01N033-537; G01N033-543; A61K031-70; A01N043-04;
C12P021-02; C12N007-00; C12N007-01; C12N005-00; C12N005-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 43 USPATFULL
AN 2002:206139 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Pyle, Ruth A., Seattle, WA, UNITED STATES
XU Jiangchun, Bellevue, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES
PI US 2002:110832 A1 20020815
PRAI US 2001-919580 A1 20010730 (9)
US 2001-302702P 20010703 (60)
US 2001-277495P 20010320 (60)
US 2000-237406P 20001002 (60)
US 2000-223265P 20000803 (60)
DT Utility
FS APPLICATION
LN.CNT 5425
INCL INCLM: 435/007.100
NCLM: 536/023.100; 530/350.000
NCLM: 435/007.100
NCLM: 536/023.100; 530/350.000
IC [7]
ICM: G01N033-53
ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 43 USPATFULL
AN 2002:171619 USPATFULL
TI Anti-lymphotoxin-beta receptor antibodies
IN as anti-tumor agents
Browning, Jeffrey L., Brookline, MA, UNITED STATES
Meier, Werner, Burlington, MA, UNITED STATES
Benjamin, Christopher D., Beverly, MA, UNITED STATES
PI US 2002:090366 A1 20020711
PRAI US 2001-931402 A1 20010816 (9)
RI Division of Ser. No. US 1998-875560, filed on 5 Jun 1998, PATENTED A 371
of International Ser. No. WO 1996-US1386, filed on 26 Jan 1996, UNKNOWN
Continuation-in-part of Ser. No. US 1995-378968, filed on 26 Jan 1995,
PENDING
DT Utility
FS APPLICATION
LN.CNT 1764
INCL INCLM: 424/094.100
INCLM: 424/178.100

NCL NCLM: 424/094.100
NCLM: 424/178.100
IC [7]
ICM: A61K039-395
ICS: A61K039-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 43 USPATFULL
AN 2002:157048 USPATFULL
TI APOPTOSIS INDUCING MOLECULE II AND METHODS OF USE
IN EBER, REINHARD, GAITHERSBURG, MD, UNITED STATES
YU, GUO-LIANG, BERKELEY, CA, UNITED STATES
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES
ZHANG, JUN, BETHESDA, MD, UNITED STATES
ULRICH, STEPHEN, ROCKVILLE, MD, UNITED STATES
ZHAI, YIFAN, GAITHERSBURG, MD, UNITED STATES
PA Human Genome Sciences (U.S. corporation)
PI US 2002:081647 A1 20020627
PRAI US 1999-252656 A1 19990219 (9)
US 1999-252656 A1 19990219 (9)
Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998,
PENDING Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan
1998, ABANDONED Continuation-in-part of Ser. No. US 1997-822953, filed
on 21 Mar 1997, ABANDONED
PRAI US 1998-754092 19980220 (60)
US 1998-139238 19980322 (60)
US 1996-301578 19961031 (60)
DT Utility
FS APPLICATION
LN.CNT 6195
INCL INCLM: 435/069.100
NCLM: 530/350.000; 530/399.000; 514/012.000; 536/023.500
NCLM: 514/012.000
NCLM: 530/300.000; 530/324.000; 530/350.000
IC [7]
ICM: A61K038-18
ICS: C12P021-06; C07H021-04; C07K014-00; G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 43 USPATFULL
AN 2002:126357 USPATFULL
TI APOPTOSIS INDUCING MOLECULE II
IN EBER, REINHARD, GAITHERSBURG, MD, UNITED STATES
YU, GUO-LIANG, DARNESTOWN, MD, UNITED STATES
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES
ULRICH, STEPHEN, ROCKVILLE, MD, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2002:064869 A1 20020530
PRAI US 1998-27287 B2 20021112
US 1998-27287 A1 19980220 (9)
RI ABANDONED
PRAI US 1996-301578 19961031 (60)
US 1996-139238 19960322 (60)
DT Utility
FS APPLICATION
LN.CNT 4242
INCL INCLM: 435/320.100
NCLM: 435/069.100; 435/325.000; 536/023.500
NCLM: 435/069.100; 435/320.100; 435/325.000; 530/324.000; 536/023.400;
NCLM: 536/023.500; 536/024.100; 930/144.000
IC [7]
ICM: C12N015-63
ICS: C07H021-04; C12N015-00; C12N015-74; C12N005-06; C12N015-70;

C12N015-09
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 43 USPTAFULL
AN 2002:119846 USPTAFULL
TI Human G-protein Chemokine receptor (CCRS) HDGNR10
IN Rosen, Craig A., Laytonville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002061834 A1 20020523
AI US 2001-779880 A1 20010209 (9)
PRAI US 2000-181258P 20000209 (60)
US 2000-187999P 20000309 (60)
US 2000-234336P 20000922 (60)
DT Utility
FS APPLICATION
LN.CNT 18667
INCL INCLM: 514/001.000
INCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100
NCLM: 514/001.000
NCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100
IC [7]
ICM: A61K031-00
ICS: C07H021-04; C07K014-705; C12N005-06; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 43 USPTAFULL
AN 2002:92268 USPTAFULL
TI Human G-protein Chemokine Receptor HDGNR10
IN Rosen, Craig A., Laytonville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002048786 A1 20020425
AI US 2001-779879 A1 20010209 (9)
PRAI US 2000-181258P 20000209 (60)
US 2000-187999P 20000309 (60)
US 2000-234336P 20000922 (60)
DT Utility
FS APPLICATION
LN.CNT 17969
INCL INCLM: 435/069.100
INCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000
NCLM: 435/069.100
NCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000
IC [7]
ICM: G01N033-53
ICS: G01N033-567; A61K038-00; C07H021-04; C12P021-06; A61K039-395;
C12N005-02; C12N005-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 43 USPTAFULL
AN 2002:67215 USPTAFULL
TI Method for detecting hepatitis C
IN Budkowska, Agata, Clamart, FRANCE
Mailard, Patrick, Montlhery, FRANCE
Bromert, Christian, Fresnes, FRANCE
Gounon, Pierre, Noisieu, FRANCE
Niklikiewicz, Jadwiga, Komorow, POLAND
Grainic, Radu, Jouy En Josas, FRANCE
INSTITUT PASTEUR, Paris Cedex, FRANCE, 75724 (non-U.S. corporation)
PI US 2002037868 A1 20020328
AI US 2001-880945 A1 20010615 (9)
PRAI US 2000-549685, filed on 14 Apr 2000,
RI1 Continuation-in-part of Ser. No. US 2000-549685, filed on 14 Apr 2000,

PENDING
PRAI US 1999-129319P 19990414 (60)
DT Utility
FS APPLICATION
LN.CNT 1656
INCL INCLM: 514/044.000
INCLS: 435/005.000; 435/007.950; 435/091.330; 435/975.000
NCLM: 514/044.000
NCLS: 435/005.000; 435/007.950; 435/091.330; 435/975.000
IC [7]
ICM: C12Q001-70
ICS: G01N033-537; G01N033-543; A61K031-70; A01N043-04;
C12P019-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 43 USPTAFULL
AN 2002:26858 USPTAFULL
TI Antagonists of tweak and of tweak receptor and their use to treat
IN Immunological disorders
IN Renner, Paul, Millis, MA, UNITED STATES
PI US 2002015703 A1 20020207
AI US 2001-905810 A1 20010713 (9)
PRAI WO 2000-US1044 20000114
US 1999-116168P 19990115 (60)
DT Utility
FS APPLICATION
LN.CNT 1303
INCL INCLM: 424/143.100
NCLM: 424/143.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 43 USPTAFULL
AN 2002:22092 USPTAFULL
TI Nucleic acid sequences associated with aging, particularly skin aging
IN Bumer, Glenna C., Seattle, WA, UNITED STATES
Brown, Joseph P., Seattle, WA, UNITED STATES
Pritchard, David, Seattle, WA, UNITED STATES
PI US 2002012927 A1 20020131
AI US 2001-802718 A1 20010308 (9)
PRAI US 2000-188584P 20000310 (60)
DT Utility
FS APPLICATION
LN.CNT 2368
INCL INCLM: 435/006.000
INCLS: 435/007.210
NCLM: 435/006.000
NCLS: 435/007.210
IC [7]
ICM: C12Q001-68
ICS: G01N033-567; A61K031-665
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 43 USPTAFULL
AN 2002:8587 USPTAFULL
TI Multivalent antibodies and uses therefor
IN Miller, Kathy L., San Francisco, CA, UNITED STATES
Presta, Leonard G., San Francisco, CA, UNITED STATES
GENENTECH, INC. (U.S. corporation)
PI US 2002004587 A1 20020110
AI US 2001-813341 A1 20010320 (9)
PRAI US 2000-195819P 20000411 (60)
DT Utility
FS APPLICATION

LN.CNT 4913
INCL INCLM: 530/388.800
NCLM: 536/023.500; 435/325.000; 435/334.000; 424/143.100
NCLM: 530/388.800
NCLM: 536/023.500; 435/325.000; 435/334.000; 424/143.100
IC [71]
ICM: C07H016-28
ICS: A61K039-395; C07H021-04; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 43 USPATFULL
AN 2002:188392 USPATFULL
TI TRAF family molecules, polynucleotides encoding them, and antibodies
against them
IN Nakano, Moromi, Yokohama, Japan
Nakano, Hiroyasu, Tokyo, Japan
Yagita, Hideo, Tokyo, Japan
Okumura, Ko, 9-2-610, Azusawa 3-chome, Itabashi-ku, Tokyo 174-0051,
Japan
PA Okumura, Ko, Tokyo, Japan (non-U.S. individual)
PI US 6426403 B1 20020730
AI US 1998-138277 19980818 (9)
RUI Continuation-in-part of Ser. No. WO 1997-JP512, filed on 24 Feb 1997
PRAI JP 1996-34674 19960222
DT Utility
FS GRANTED

LN.CNT 1694
INCL INCLM: 530/350.000
NCLM: 530/351.000; 435/069.100; 536/023.100
NCLM: 530/350.000
NCLM: 530/350.000
NCLM: 435/069.100; 530/351.000; 536/023.100
IC [71]
ICM: C07H014-52
ICS: C07H021-04; C12N015-00
EXP 530/350.000; 530/351.000; 435/183.435/174; 435/69.11; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 43 USPATFULL
AN 2002:152777 USPATFULL
TI Nucleic acid encoding a TRAF-3 deletion isoform
IN Lederman, Seth, New York, NY, United States
Van Eynhoven, Winfried, BaySide, NY, United States
PA The Trustees of the University in the City of New York, New York, NY,
United States (U.S. corporation)
PI US 6410710 B1 20020625
AI US 1999-268544 19990311 (9)
DT Utility
FS GRANTED

LN.CNT 3011
INCL INCLM: 536/023.500
NCLM: 536/023.100; 435/320.100
NCLM: 536/023.500
NCLM: 435/320.100; 536/023.100
IC [71]
ICM: C07H021-04
ICS: C12N015-11; C12N015-63
EXP 536/23.1; 536/23.5; 435/320.1; 424/93.1; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 43 USPATFULL
AN 2002:136562 USPATFULL
TI Soluble lymphotoxin-beta receptors as
therapeutic agents for the treatment of immunological disease
IN Browning, Jeffrey L., Brookline, MA, United States
Benjamin, Christopher D., Beverly, MA, United States

PA Hochman, Paula S., Newton, MA, United States
Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6403087 B1 20020611
MO 9703687 19970206 19980608 (9)
AI US 1998-166 19960719
WO 1996-US12010 19960719

RUI Continuation-in-part of Ser. No. US 1995-505606, filed on 21 Jul 1995,
now patented, Pat. No. US 5925351
DT Utility
FS GRANTED

LN.CNT 1983
INCL INCLM: 424/134.100
NCLM: 424/134.100; 424/133.100; 514/002.000; 514/008.000; 530/387.100;
530/387.300
NCLM: 424/134.100
NCLM: 424/133.100; 514/002.000; 514/008.000; 530/387.100; 530/387.300
IC [71]
ICM: A61K039-395
ICS: A61K038-16
EXP 424/148.1; 424/144.1; 424/145.1; 424/156.1; 514/2; 514/8; 530/395;
530/387.1; 530/388.22; 530/388.23; 530/388.73; 530/388.85; 530/389.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 43 MEDLINE
AN 2002378234 MEDLINE
DN 22119432 PubMed ID: 12124338
TI Lymphotoxin-beta receptor immune interaction
AU Promotes tumor growth by inducing angiogenesis.
Hehlhans Thomas; Stoelcker Benjamin; Stopfer Peter; Muller Peter;
Cernianu Grigore; Gaba Markus; Steinhauer Markus; Nedospasov Sergei A;
Pfeffer Klaus; Mannel Daniela N
CS Department of Pathology/Tumor Immunology, University of Regensburg,
D-93042 Regensburg, Germany.
SO CANCER RESEARCH. (2002 Jul 15) 62 (14) 4034-40.
Journal code: 2984705R. ISSN: 0008-5472.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200208
ED Entered STN: 20020719
Last Updated on STN: 20020814
Entered Medline: 20020813

L6 ANSWER 22 OF 43 MEDLINE
AN 2002415478 MEDLINE
DN 22159812 PubMed ID: 12169272
TI Lymphotoxin beta receptor induces
interleukin 8 gene expression via NF-kappaB and AP-1 activation.
AU Chang Ying-Hsin; Hsieh Shie-Liang; Chen Wei-Chieh; Lin Wan-Wan
CS Department of Pharmacology, College of Medicine, National Taiwan
University, Taipei, Taiwan.
SO EXPERIMENTAL CELL RESEARCH. (2002 Aug 15) 278 (2) 166-74.
Journal code: 0373226. ISSN: 0014-4827.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200209
ED Entered STN: 20020810
Last Updated on STN: 20021002
Entered Medline: 20020913

L6 ANSWER 23 OF 43 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 2003:5196 BIOSIS
 DN PREV20030005196
 TI Lymphotoxin-beta receptor activation
 AU Hehlhans, T. (1); Stoelcker, B. (1); Stoefer, P. (1); Steinbauer, M.;
 Pfeiffer, K.; Maennel, D. N. (1)
 CS (1) Institute of Pathology/Tumor Immunology, Technical University of
 Munich, Munich, Germany
 SO Journal of Interferon and Cytokine Research, (2002) Vol. 22, No.
 Supplement 1, pp. S-113. Print.
 Meeting Info.: Joint Meeting of the International Society for Interferon
 and Cytokine Research, the International Cytokine Society, the Society for
 Leukocyte Biology, and the European Cytokine Society on Cytokines and
 Interferons Turin, Italy October 06-10, 2002 International Society for
 Interferon and Cytokine Research
 . ISSN: 1079-9907.
 DT Conference
 LA English

L6 ANSWER 24 OF 43 USPATFUL
 AN 2001:231143 USPATFUL
 TI Arrays for identifying agents which mimic or inhibit the activity of
 interferons
 IN Silverman, Robert H., Beachwood, OH, United States
 Williams, Bryan R. G., Cleveland, OH, United States
 Der, Sandy, Cleveland, OH, United States
 PA The Cleveland Clinic Foundation, Cleveland, OH, United States (U.S.
 corporation)
 PI US 6331396 B1 20011218
 AI US 1999-405438 19990923 (9)
 PRAI US 1998-101497P 19980923 (60)
 DT Utility
 FS GRANTED
 LN.CNT 9639
 INCL INCLM: 435/006.000
 NCLM: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
 NCLM: 435/006.000
 NCLM: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
 IC [7]
 ICM: C120001-68
 EKF ICS: C12M001-36; C07H021-04
 435/6; 435/287.2; 536/23.1; 536/24.31; 536/23.52
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 43 USPATFUL
 AN 2001:196600 USPATFUL
 TI Lymphotoxin-.alpha./beta. complexes and anti-Lymphotoxin-.beta. receptor
 antibodies as anti-tumor agents
 IN Browning, Jeffrey L., 32 Milton Rd., Brookline, MA, United States 02146
 Weiler, Werner, 31 Bedford St., Burlington, MA, United States 01803
 Benjamin, Christopher D., 2 Oak Hill La., Beverly, MA, United States
 01915
 PI US 6312691 B1 20011106
 AI WO 9622788 19960801
 US 1998-875560 19980605
 WO 1996-US1386 19980605
 PCT 371 date
 FCT 102(e) date
 DT Utility
 FS GRANTED
 LN.CNT 2254
 INCL INCLM: 424/143.100
 INCLM: 424/130.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;
 530/388.750; 530/388.800; 530/388.850
 NCLM: 424/143.100

NCLM: 424/130.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;
 530/388.750; 530/388.800; 530/388.850
 IC [7]
 ICM: A61K039-395
 EKF 424/130.1; 424/143.1; 424/144.1; 424/809; 530/388.22; 530/388.7;
 530/388.75; 530/388.8; 530/388.85
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 26 OF 43 USPATFUL
 AN 2001:75530 USPATFUL
 TI Fas ligand-like protein, its production and use
 IN Nishi, Kazunori, Ibaraki, Japan
 Hikichi, Yukiko, Ibaraki, Japan
 Shintani, Yasushi, Ibaraki, Japan
 PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
 PI US 6235878 B1 20010522
 WO 9803648 19980129
 WO 1997-JP2480 19970904 (8)
 AI 19970717
 19970904
 19970904
 PCT 371 date
 FCT 102(e) date
 PRAI JP 1996-191204 19960719
 JP 1996-211695 19960809
 JP 1997-19330 19970131
 DT Utility
 FS GRANTED
 LN.CNT 4854
 INCL INCLM: 530/350.000
 NCLM: 530/350.000
 IC [7]
 ICM: C07K001-00
 EKF 530/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 43 USPATFUL
 AN 2001:44016 USPATFUL
 TI Proteins capable of regulating NF-kappa.B JNK and apoptosis pathways
 and methods of using the same
 IN Chaudhary, Preet M., Dallas, TX, United States
 Hood, Leroy, Seattle, WA, United States
 PA University of Washington/Stowers Institute for Medical Research, United
 States (U.S. corporation)
 PI US 6207458 B1 20010327
 US 1998-74004 19980507 (9)
 AI US 1998-74004 19980507 (9)
 DT Utility
 FS GRANTED
 LN.CNT 1982
 INCL INCLM: 435/503.000
 INCLM: 435/004.000; 435/007.100; 435/007.720; 435/018.000; 435/023.000;
 435/040.500; 435/040.510; 435/040.520
 NCLM: 435/004.000
 NCLM: 435/004.000; 435/007.100; 435/007.720; 435/018.000; 435/023.000;
 435/040.500; 435/040.510; 435/040.520
 IC [7]
 ICM: C120001-37
 EKF ICS: C12M001-90; G01N033-567; G01N033-18; G01N033-53
 435/503; 435/4; 435/7.1; 435/7.72; 435/18; 435/23; 435/40.5; 435/40.51;
 435/40.52
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 43 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:100086 CAPLUS
 DN 134:265112
 TI Signal via Lymphotoxin-.beta.R on bone marrow stromal cells is required
 for an early checkpoint of NK cell development

AN	Wu, Qiang; Sun, Yongliang; Wang, Jing; Jin, Xiaodui; Wang, Yang; Pegg, Lyly		
AV	E.; Futerer, Agnes; Pfeffer, Klaus; Fu, Yang-Xin		
CS	Department of Pathology, University of Chicago, Chicago, IL, 60637, USA		
SO	Journal of Immunology (2001), 166(3), 1684-1689		
ED	CODEN: JOMIA3; ISSN: 0022-1767		
PB	American Association of Immunologists		
DT	Journal		
LA	English		
RE	CNT 28		
THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD			
ALL CITATIONS AVAILABLE IN THE RE FORMAT			
LN	ANSWER 29 OF 43	MEDLINE	DUPLICATE 3
L6	2001246642	MEDLINE	
DN	21136241	PubMed ID: 11238592	
TI	Molecular basis for hematopoietic/mesenchymal interaction during		
AV	initiation of Peyer's patch organogenesis.		
CS	Honda K; Nakano H; Yoshida T; Chiba T; Nishikawa S; I		
SO	Department of Molecular Genetics, Graduate School of Medicine, Kyoto		
ED	University, Syogoin-Kawhachacho 53, Sakyo-ku, Kyoto 606-8507, Japan..		
DT	khorasavivrus.kyoto-u.ac.jp		
LA	JOURNAL OF EXPERIMENTAL MEDICINE, (2001 Mar 5) 193 (5) 621-30.		
FS	United States		
EM	Journal code: 29651098. ISSN: 0022-1007.		
DT	Journal; Article; (JOURNAL ARTICLE)		
LA	English		
FS	Priority Journals		
EM	200105		
ED	Entered STN: 20010517		
DT	Last Updated on STN: 20010517		
LA	Entered Medline: 20010510		
L6	ANSWER 30 OF 43	MEDLINE	DUPLICATE 4
DN	2001331753	MEDLINE	
TI	Functional characterization of the mouse lymphotoxin-		
AV	beta receptor promoter.		
CS	Muller P; Mannel D N; Hahlgans T		
SO	Institute of Pathology and Tumor Immunology, University of Regensburg,		
ED	D-93042 Regensburg, Germany.		
CY	EUROPEAN CYTOKINE NETWORK, (2001 Apr-Jun) 12 (2) 325-30.		
DT	Journal code: 9100879. ISSN: 1148-5493.		
LA	France		
FS	Journal; Article; (JOURNAL ARTICLE)		
EM	English		
ED	Priority Journals		
EM	200109		
ED	Entered STN: 20010910		
DT	Last Updated on STN: 20010910		
LA	Entered Medline: 20010906		
L6	ANSWER 31 OF 43	CAPLUS	COPYRIGHT 2003 ACS
LN	2001570450	CAPLUS	
DN	1353287475		
TI	Bridging the NFAT and NF-kappa.B families: NFAT5 dimerization regulates		
AV	cytokine gene transcription in response to osmotic stress		
CS	Lopez-Rodriguez, Cristina; Aramburu, Jose; Jin, Lei; Rakeman, Andrew S.;		
SO	Michino, Mayako; Rao, Anjana		
ED	The Center for Blood Research and Department of Pathology, Harvard Medical		
DT	School, Boston, MA, 02115, USA		
LA	Immunology (2001), 15(1), 47-58		
FS	CODEN: JUMTEH; ISSN: 1074-7613		
EM	Cell Press		
DT	Journal		
LA	English		

TI Characterization of the mouse lymphotoxin-beta receptor promoter.
 AU Mueller, P. (1); Hehlhans, T. (1); Maennel, D. N. (1)
 CS (1) Institute of Pathology/Tumorimmunology, University of Regensburg, Regensburg Germany
 SO Scandinavian Journal of Immunology, (June, 2000) Vol. 51, No. Supplement 1, pp. 60. print.
 DT Meeting Info.: 8th International TNF Congress, Conference on Tumor Necrosis Factor and Related Molecules Scientific Advances and Medical Applications Tondheim, Norway May 14-18, 2000
 LA English
 SL English
 L6 ANSWER 36 OF 43 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 AN 2000/416045 BIOSIS
 DN PREV200000416045
 TI Lymphotoxin-beta receptor activation
 AU Hehlhans, T. (1); Stoelcker, B. (1); Steinbauer, M.; Pfeiffer, K.; Maennel, D. N. (1)
 CS (1) Institute of Pathology/Tumorimmunology, Technical University of Munich, Munich Germany
 SO Scandinavian Journal of Immunology, (June, 2000) Vol. 51, No. Supplement 1, pp. 39. print.
 DT Meeting Info.: 8th International TNF Congress, Conference on Tumor Necrosis Factor and Related Molecules Scientific Advances and Medical Applications Tondheim, Norway May 14-18, 2000
 LA English
 SL English
 L6 ANSWER 37 OF 43 CAPLUS COPYRIGHT 2003 ACS
 AN 2000/477615 CAPLUS
 DN 133:23392
 TI Detection of protein-protein interactions using a green fluorescent protein-based mammalian two-hybrid system
 AU Forin-Mieczek, M.; Rottmann, M.; Rehg, G.; Rupp, S.; Johannes, F.-J.; Fraunhofer Institute for Interfacial Engineering and Biotechnology, Stuttgart, 70569, Germany
 CS Biotechniques (2000), 29 (1), 22-24, 26
 SO CODEN: BTNDOD; ISSN: 0736-6205
 PB Eaton Publishing Co.
 DT Journal
 LA English
 RE.CNT 11
 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

INCL: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000; 530/395.000; 530/387.100; 530/388.220; 530/388.230; 530/388.720; 530/388.850; 530/389.200
 NCL NCLM: 424/143.100
 NCLM: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000; 530/387.100; 530/388.220; 530/388.230; 530/388.720; 530/388.850; 530/389.200; 530/395.000
 IC [6]
 ICM: A61K039-395
 EXF ICS: A61K038-16; C07K016-00; C07K016-28
 514/218; 530/395; 530/387.1; 530/388.22; 530/388.23; 530/388.73; 530/388.85; 530/389.2; 424/143.1; 424/144.1; 424/145.1; 424/156.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L6 ANSWER 39 OF 43 CAPLUS COPYRIGHT 2003 ACS
 AN 1999/456745 CAPLUS
 DN 131:241771
 TI Requirement for membrane lymphotoxin in natural killer cell development
 AU Iizuka, Koho; Chaplin, David D.; Wang, Yang; Wu, Qiang; Peggs, Lyle E.; Yokoyama, Wayne M.; Fu, Yang-Xin
 CS Departments of Internal Medicine and Pathology, Howard Hughes Medical Institute, and Center for Immunology, Washington University School of Medicine, St. Louis, MO, 63110, USA
 SO Proceedings of the National Academy of Sciences of the United States of America (1999), 96 (11), 6336-6340
 CODEN: PNASDA; ISSN: 0027-8424
 PB National Academy of Sciences
 DT Journal
 LA English
 RE.CNT 28
 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

INCL: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000; 530/395.000; 530/387.100; 530/388.220; 530/388.230; 530/388.720; 530/388.850; 530/389.200
 NCL NCLM: 424/143.100
 NCLM: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000; 530/387.100; 530/388.220; 530/388.230; 530/388.720; 530/388.850; 530/389.200; 530/395.000
 L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2003 ACS
 AN 1999/594139 CAPLUS
 DN 131:298517
 TI The requirement of membrane lymphotoxin for the presence of dendritic cells in lymphoid tissues
 AU Wu, Qiang; Wang, Yang; Wang, Jing; Hedgeman, Elizabeth O.; Browning, Jeffrey L.; Fu, Yang-Xin
 CS Department of Pathology, The University of Chicago, Chicago, IL, 60637, USA
 SO Journal of Experimental Medicine (1999), 190 (5), 629-638
 CODEN: JEMEDV; ISSN: 0022-1007
 PB Rockefeller University Press
 DT Journal
 LA English
 RE.CNT 32
 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

INCL: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000; 530/395.000; 530/387.100; 530/388.220; 530/388.230; 530/388.720; 530/388.850; 530/389.200
 NCL NCLM: 424/143.100
 NCLM: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000; 530/387.100; 530/388.220; 530/388.230; 530/388.720; 530/388.850; 530/389.200; 530/395.000
 L6 ANSWER 41 OF 43 MEDLINE
 AN 1998216728 MEDLINE
 DN 98216728 PubMed ID: 9557650
 TI Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.
 AU Zhu N; Khoshnaw A; Schneider R; Matsumoto M; Denhart G; Ware C; Lai M M
 CS Department of Molecular Microbiology and Immunology, University of Southern California School of Medicine, Los Angeles 90033, USA.
 SO JOURNAL OF VIROLOGY, (1998 May) 72 (5) 3691-7.
 CY United States
 DT Journal; Article: (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199805
 ED Entered STM: 19980529

Last Updated on STN: 20021008
Entered Medline: 19980520

L6 ANSWER 42 OF 43 CAPLUS COPYRIGHT 2003 ACS
AN 1998:417179 CAPLUS
DN 129:160479
TI Effects of tumor necrosis factor and lymphotoxin on peripheral lymphoid
tissue development
AU Ettinger, Rachel; Mebius, Reina; Browning, Jeffrey L.; Michie, Sara A.;
Van Tuijl, Silvy; Kraal, George; Van Ewijk, Willem; McDevitt, Hugh O.
CS Dep. Microbiol. Immunol., Stanford Univ. Sch. Med., Stanford, CA,
94305-5402, USA
SO International Immunology (1998), 10(6), 727-741
PB CODEN: INIMEN, ISSN: 0953-8178
DT Oxford University Press
LA English
RE.CNT 13
THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 43 OF 43 MEDLINE DUPLICATE 6
AN 97075125 MEDLINE
DN 97075125 PubMed ID: 8917551
TI Disrupted splenic architecture, but normal lymph node development in mice
expressing a soluble lymphotoxin-beta receptor
AU Ettinger R, Browning J L, Michie S A, van Ewijk W, McDevitt H O
CS Department of Microbiology and Immunology, Stanford University School of
Medicine, CA 94305, USA.
NC AI-36535 (MIAID)
CA-48734 (NCI)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA. (1996 Nov 12) 93 (23) 13102-7.
Journal code: 7505876. ISSN: 0027-8424.
CY United States
DT Journal Article: (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199612
ED Entered STN: 19970128
Last Updated on STN: 19970128
Entered Medline: 19961230

=> d his

(FILE 'HOME' ENTERED AT 12:32:53 ON 11 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, EMBASE, CAPLUS, USPATFULL',
ENTERED AT 12:33:20 ON 11 FEB 2003
L1 136 S LYMPHOTOXIN (A) BETA (A) RECEPTOR AND ANTIBODY?
L2 42 S L1 AND INTERFERON?
L3 34 DUP REM L2 (8 DUPLICATES REMOVED)
L4 541 S LYMPHOTOXIN (A) BETA (A) RECEPTOR
L5 66 S L4 AND PROMOT
L6 43 DUP REM L5 (23 DUPLICATES REMOVED)

=> b 14 and cancer
L7 48 L4 AND CANCER

=> dup rem 17
L8 PROCESSING COMPLETED FOR L7
39 DUP REM L7 (9 DUPLICATES REMOVED)

=> d 1-39

L8 ANSWER 1 OF 39 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1
AN 2002:409195 CAPLUS
DN 137:1567
TI Human apoptosis inducing molecule II and its cDNA and use thereof in drug
screening and therapy
AU Ebner, Reinhard; Yu, Guo-liang; Ruben, Steven M.; Ullrich, Stephen
PA Human Genome Sciences, Inc., USA
SO U.S. Pat. Appl. Publ., 79 pp., Cont.-in-part of U.S. Ser. No. 822,953,
abandoned.
DT Patent
LA English
FAN.CNT 5
PATENT NO. KIND DATE APPLICATION NO. DATE

PI US 2002064869 A1 20020530 US 1998-27287 19980220
US 6479254 B2 20021112 CA 1999-231057 19990107
CA 2317057 AA 19990715 MO 1999-US242 19990107
MO 9935262 A2 19990715
MO 9935262 A3 19991202

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GD, GE, GH, GR, GU, HK, HU, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, BG, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GM, ML, MR, NE, SN, TD, TG
AU 9921063 A1 19990726 AU 1999-21063 19990107
EP 1044270 A1 20001018 EP 1999-901341 19990107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

JP 2002500043 T2 20020108 JP 2000-527646 19990107
CA 2321186 AA 19990826 CA 1999-2321186 19990219
WO 9942584 A1 19990826 WO 1999-US3703 19990219
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GD, GE, GH, GR, GU, HK, HU, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, BG, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GM, ML, MR, NE, SN, TD, TG
AU 9929721 A1 19990906 AU 1999-29721 19990219
EP 1054968 A1 20001129 EP 1999-910970 19990219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

JP 200250433 T2 20020212 JP 2000-532524 19990219
US 2002081647 A1 20020627 US 1999-25256 19990219
US 6495520 B2 20021217
US 1996-13923P P 19960322
PRAI US 1996-30157P P 19961031
US 1997-822953 A 19970321
US 1998-3886 A 19980107
US 1998-27287 A 19980220
US 1998-75409P P 19980220
WO 1999-US242 W 19990107
WO 1999-US3703 W 19990219

L8 ANSWER 2 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2002:555371 CAPLUS
DN 137:139348
TI Molecular antigen array for vaccines against infectious disease.

[illegible]

PRAI US 2001-303224P 20010706 (60)
 US 2000-252131P 20001121 (60)
 US 2000-227598P 20000825 (60)
 US 1999-168235P 19991201 (60)
 US 1999-146379P 19990802 (60)
 US 1999-131964P 19990430 (60)
 US 1999-131270P 19990427 (60)
 US 1999-124092P 19990312 (60)
 US 1999-121774P 19990304 (60)
 US 1997-35496P 19970114 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 12989
 INCL INCLM: 424/178.100
 INCL INCLM: 530/389.100
 NCLM: 424/178.100
 NCLM: 530/389.100
 IC [7]
 ICM: A61K039-395
 ICS: C07K016-46

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 39 USPTFPU
 AN 2002:259408 USPTFPU
 TI Gene expression profiles in liver cancer
 IN Horne, Barci T.; Galtersburg, MD, UNITED STATES
 Scherf, Uwe, Galtersburg, MD, UNITED STATES
 Vockley, Joseph, Damascus, MD, UNITED STATES
 PI US 2002:42381 AI 20021003
 AI US 2001-880107 AI 20010614 (9)
 PRAI US 2000-211379P 20000614 (60)
 US 2000-237054P 20001002 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 15937
 INCL INCLM: 514/044.000
 INCL INCLM: 435/006.000
 NCLM: 514/044.000
 NCLM: 435/006.000
 IC [7]
 ICM: A61K048-00
 ICS: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 39 USPTFPU
 AN 2002:235448 USPTFPU
 TI Human tumor necrosis factor receptor-like protein 8
 IN Li, Jian, Rockville, MD, UNITED STATES
 Moore, Paul A., Germantown, MD, UNITED STATES
 PI US 2002:127637 AI 20020912
 AI US 2001-768779 AI 20010125 (9)
 RLI Continuation of Ser. No. US 1998-86582, filed on 29 May 1998, ABANDONED
 PRAI US 1997-48020P 19970529 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3860
 INCL INCLM: 435/069.100
 INCL INCLM: 435/320.100; 435/325.000; 530/350.000; 536/023.500
 NCLM: 435/069.100
 NCLM: 435/320.100; 435/325.000; 530/350.000; 536/023.500
 IC [7]
 ICM: C07K014-715
 ICS: C12P021-02; C12N005-06; C07H021-04
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 39 USPTFPU
 AN 2002:235426 USPTFPU
 TI TRAF-3 deletion isoforms and uses thereof
 IN Lederman, Seth, New York, NY, UNITED STATES
 Brydowen, Manfred Van, Bellport, NY, UNITED STATES
 PI US 2002:127615 AI 20020912
 AI US 2001-950902 AI 20010910 (9)
 RLI Continuation of Ser. No. WO 2000-US6503, filed on 10 Mar 2000, UNKNOWN
 Continuation-in-part of Ser. No. US 1999-268544, filed on 11 Mar 1999,
 PENDING
 DT Utility
 FS APPLICATION
 LN.CNT 4140
 INCL INCLM: 435/007.210
 INCL INCLM: 435/183.000; 435/325.000; 435/320.100; 530/350.000; 536/023.200
 NCLM: 435/007.210
 NCLM: 435/183.000; 435/325.000; 435/320.100; 530/350.000; 536/023.200
 IC [7]
 ICM: G01N033-567
 ICS: C07H021-04; C12N009-00; C07K014-705

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 39 USPTFPU
 AN 2002:228312 USPTFPU
 TI Treatment of autoimmune disease
 IN Faustman, Denise, Weston, MA, UNITED STATES
 PI US 2002:123472 AI 20020905
 AI US 2001-768769 AI 20010123 (9)
 RLI Continuation-in-part of Ser. No. US 2000-521064, filed on 8 Mar 2000,
 ABANDONED
 PRAI US 1999-123738P 19990310 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1830
 INCL INCLM: 514/044.000
 INCL INCLM: 435/005.000; 435/235.100; 435/325.000; 435/007.920; 435/069.500
 NCLM: 514/044.000
 NCLM: 435/005.000; 435/235.100; 435/325.000; 435/007.920; 435/069.500
 IC [7]
 ICM: C12Q001-70
 ICS: G01N033-53; G01N033-543; A61K031-70; A01N043-04;
 C12P021-02; C12N007-00; C12N007-01; C12N005-00; C12N005-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 39 USPTFPU
 AN 2002:206139 USPTFPU
 TI Compositions and methods for the therapy and diagnosis of colon
 cancer
 IN Pyle, Ruth A., Seattle, WA, UNITED STATES
 Xu, Jiangchun, Bellevue, WA, UNITED STATES
 Secrett, Heather, Seattle, WA, UNITED STATES
 PA Corix Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
 PI US 2002:110832 AI 20020815
 AI US 2001-919580 AI 20010710 (9)
 PRAI US 2001-302702P 20010703 (60)
 US 2001-277495P 20010320 (60)
 US 2000-237406P 20001002 (60)
 US 2000-223265P 20000803 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5425
 INCL INCLM: 435/007.100
 INCL INCLM: 536/023.100; 530/350.000
 NCLM: 435/007.100
 NCLM: 536/023.100; 530/350.000

IC [7]
 ICM: G01N033-53
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 39 USPTAFULL
 AN 2002:171619 USPTAFULL
 TI Anti-lymphotoxin-beta receptor antibodies
 IN as anti-tumor agents
 PI Browning, Jeffrey L., Brookline, MA, UNITED STATES
 PI Meier, Werner, Burlington, MA, UNITED STATES
 PI Benjamin, Christopher D., Beverly, MA, UNITED STATES
 PI US 2002090366 A1 20020721
 PI US 2001-931402 A1 20010816 (9)
 RLI Division of Ser. No. US 1998-873560, filed on 5 Jun 1998, PATENTED A 371
 of International Ser. No. WO 1996-US1386, filed on 26 Jan 1996, UNKNOWN
 Continuation-in-part of Ser. No. US 1995-378968, filed on 26 Jan 1995,
 PENDING

DT Utility
 FS APPLICATION
 LN.CNT 1764
 INCL INCLM: 424/094.100
 NCL INCLM: 424/178.100
 NCLM: 424/094.100
 NCLS: 424/178.100
 IC [7]
 ICM: A61K039-395
 ICS: A61K039-40
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 39 USPTAFULL
 AN 2002:157048 USPTAFULL
 TI APOPTOSIS INDUCING MOLECULE II AND METHODS OF USE
 IN EBNER, REINHARD, GAITHERSBURG, MD, UNITED STATES
 YU, GUO-LIANG, BERKELEY, CA, UNITED STATES
 RUBEN, STEVEN M., OLNEY, MD, UNITED STATES
 ZHANG, JUN, BETHESDA, MD, UNITED STATES
 ULATICH, STEPHEN, ROCKVILLE, MD, UNITED STATES
 ZHAI, YIFAN, GAITHERSBURG, MD, UNITED STATES
 PA Human Genome Sciences (U.S. Corporation)
 PI US 2002081647 A1 20020627
 PI US 6495520 B2 20021217
 AI US 1998-252656 A1 19990219 (9)
 RLI Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998,
 PENDING Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan
 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-822953, filed
 on 21 Mar 1997, ABANDONED
 PRAI US 1998-75409P 19980220 (60)
 US 1996-13923P 19960322 (60)
 US 1996-30157P 19961031 (60)

DT Utility
 FS APPLICATION
 LN.CNT 6195
 INCL INCLM: 435/069.100
 NCL INCLM: 530/350.000; 530/399.000; 514/012.000; 536/023.500
 NCLM: 514/012.000
 NCLS: 530/300.000; 530/324.000; 530/350.000
 IC [7]
 ICM: A61K038-18
 ICS: C12P021-06; C07H021-04; C07K014-00; G01N033-53
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 39 USPTAFULL
 AN 2002:119846 USPTAFULL
 TI Human G-protein Chemokine receptor (CCR5) HDGMR10

IN Rosen, Craig A., Laytonville, MD, UNITED STATES
 Roschke, Viktor, Rockville, MD, UNITED STATES
 LI, YA, Sunnyvale, CA, UNITED STATES
 RUBEN, STEVEN M., OLNEY, MD, UNITED STATES
 PI US 2002061834 A1 20020523
 AI US 2001-779880 A1 20010209 (9)
 PRAI US 2000-181258P 20000209 (60)
 US 2000-187999P 20000309 (60)
 US 2000-234336P 20000922 (60)

DT Utility
 FS APPLICATION
 LN.CNT 18667
 INCL INCLM: 514/001.000
 NCL INCLM: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100
 NCLM: 514/001.000
 NCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100
 IC [7]
 ICM: A61K031-00
 ICS: C07H021-04; C07K014-705; C12N005-06; C12P021-02
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 39 USPTAFULL
 AN 2002:92268 USPTAFULL
 TI Human G-protein Chemokine Receptor HDGMR10
 IN ROSEN, CRAIG A., LAYTONVILLE, MD, UNITED STATES
 ROSCHKE, VIKTOR, ROCKVILLE, MD, UNITED STATES
 LI, YA, Sunnyvale, CA, UNITED STATES
 RUBEN, STEVEN M., OLNEY, MD, UNITED STATES
 PI US 2002048786 A1 20020425
 AI US 2001-779879 A1 20010209 (9)
 PRAI US 2000-181258P 20000209 (60)
 US 2000-187999P 20000309 (60)
 US 2000-234336P 20000922 (60)

DT Utility
 FS APPLICATION
 LN.CNT 17969
 INCL INCLM: 435/069.100
 NCL INCLM: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000
 NCLM: 435/069.100
 NCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000
 IC [7]
 ICM: G01N033-53
 ICS: G01N033-567; A61K038-00; C07H021-04; C12P021-06; A61K039-395;
 C12N005-02; C12N005-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 39 USPTAFULL
 AN 2002:72443 USPTAFULL
 TI Method for the high level expression of active lymphotoxin-beta receptor immunoglobulin chimeric proteins and their purification
 IN Browning, Jeffrey, Brookline, MA, UNITED STATES
 Matkowski, Konrad, North Reading, MA, UNITED STATES
 Meier, Werner, Burlington, MA, UNITED STATES
 PI US 2002039580 A1 20020404
 AI US 2001-767370 A1 20010123 (9)
 RLI Continuation of Ser. No. WO 1999-US29873, filed on 16 Dec 1999, UNKNOWN
 PRAI US 1998-112752P 19981217 (60)

DT Utility
 FS APPLICATION
 LN.CNT 1163
 INCL INCLM: 424/178.100
 NCL INCLM: 530/389.100; 435/069.700; 435/328.000; 530/351.000
 NCLM: 424/178.100
 NCLS: 530/389.100; 435/069.700; 435/328.000; 530/351.000

IC [7]
ICM: A61K039-395
ICS: C12P021-04; C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 39 USPATFILL
AN 2002:22092 USPATFILL
TI Nucleic acid sequences associated with aging, particularly skin aging
IN Brown, Glenn C., Seattle, WA, UNITED STATES
Brown, Joseph P., Seattle, WA, UNITED STATES
Pritchard, David, Seattle, WA, UNITED STATES
PI US 2002012927 A1 20020131
AI US 2001-802718 A1 20010308 (9)
PRAI US 2000-188584P 20000310 (60)
DT Utility
FS APPLICATION
LN.CNT 2368
INCL INCLM: 435/006.000
INCLS: 435/007.210
NCL NCLM: 435/006.000
NCLS: 435/007.210
IC [7]
ICM: C12N001-68
ICS: C01N033-567; A61K031-665
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 39 USPATFILL
AN 2002:8587 USPATFILL
TI Multivalent antibodies and uses therefor
IN Miller, Kathy L., San Francisco, CA, UNITED STATES
Presta, Leonard G., San Francisco, CA, UNITED STATES
GENENTECH, INC. (U.S. corporation)
PI US 2002004587 A1 20020110
AI US 2001-813341 A1 20010320 (9)
PRAI US 2000-195819P 20000411 (60)
DT Utility
FS APPLICATION
LN.CNT 4913
INCL INCLM: 530/388.800
INCLS: 536/023.500; 435/325.000; 435/334.000; 424/143.100
NCL NCLM: 530/388.800
NCLS: 536/023.500; 435/325.000; 435/334.000; 424/143.100
IC [7]
ICM: C07K036-28
ICS: A61K039-395; C07H021-04; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 39 USPATFILL
AN 2002:188392 USPATFILL
TI TRAF family molecules, polynucleotides encoding them, and antibodies
IN against them
Nakata, Motomi, Yokohama, JAPAN
Nakano, Hiroyasu, Tokyo, JAPAN
Yagita, Hideo, Tokyo, JAPAN
Okumura, Ko, 9-2-610, Azusawa 3-chome, Itabashi-ku, Tokyo 174-0051, JAPAN
PI US 6426403 B1 20020730
AI US 1998-138277 19980818 (9)
RLI Continuation-in-part of Ser. No. WO 1997-JP512, filed on 24 Feb 1997
PRAI JP 1996-14674 19960222
DT Utility
FS GRANTED
LN.CNT 1694
INCL INCLM: 530/350.000

NCL INCLM: 530/351.000; 435/069.100; 536/023.100
NCLM: 530/350.000
NCLS: 435/069.100; 530/351.000; 536/023.100
IC [7]
ICM: C07K014-52
ICS: C07H021-04; C12N015-00
EXF 530/300; 530/350; 530/351; 435/183; 435/174; 435/69.1; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 39 USPATFILL
AN 2002:152777 USPATFILL
TI Nucleic acid encoding a TRAF-3 deletion isoform
IN Lederman, Seth, New York, NY, United States
Van Eyndhoven, Winfried, Bayside, NY, United States
The Trustees of the University in the City of New York, New York, NY.
PI US 6410710 B1 20020625
AI US 1999-268544 19990311 (9)
PRAI US 1999-268544 19990311 (9)
DT Utility
FS GRANTED
LN.CNT 3011
INCL INCLM: 536/023.500
INCLS: 536/023.100; 435/320.100
NCL NCLM: 536/023.500
NCLS: 435/320.100; 536/023.100
IC [7]
ICM: C07H021-04
ICS: C12N015-11; C12N015-63
EXF 536/23.1; 536/23.5; 435/320.1; 424/93.1; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 39 USPATFILL
AN 2002:136562 USPATFILL
TI Soluble lymphotoxin-beta receptors as
IN therapeutic agents for the treatment of immunological disease
Browning, Jeffrey U., Brookline, MA, United States
Benjamin, Christopher D., Beverly, MA, United States
Hochman, Paula S., Newton, MA, United States
BioGen, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6463087 B1 20020611
AI US 9703687 19970206
WO 9703687 19970206
US 1998-166 19980608 (9)
WO 1996-US12010 19960719
RLI Continuation-in-part of Ser. No. US 1995-505606, filed on 21 Jul 1995.
now patented, Pat. No. US 5925351
DT Utility
FS GRANTED
LN.CNT 1983
INCL INCLM: 424/134.100
INCLS: 424/134.100; 424/133.100; 514/002.000; 514/008.000; 530/387.100;
530/387.300
NCL NCLM: 424/134.100
NCLS: 424/133.100; 514/002.000; 514/008.000; 530/387.100; 530/387.300
IC [7]
ICM: A61K039-395
ICS: A61K038-16
EXF 424/148.1; 424/144.1; 424/145.1; 424/156.1; 514/2; 514/8; 530/395;
530/397.1; 530/388.22; 530/388.23; 530/388.73; 530/388.85; 530/389.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 39 USPATFILL
AN 2002:129717 USPATFILL
TI Antisense modulation of expression of tumor necrosis factor
receptor-associated factors (TRAFs)

IN Baker, Brenda F., Carlsbad, CA, United States
 Comert, Lex M., Carlsbad, CA, United States
 Monta, Brett P., La Costa, CA, United States
 Xu, Xiaoxing S., Madsen, NJ, United States
 PA ISS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. Corporation)
 PI US 639297 B1 20020604
 AI US 1998-167109 19981006 (9)
 DT Utility
 FS GRANTED
 LN.CNT 2151
 INCL INCLM: 435/006.000
 INCLM: 435/091.100; 435/375.000; 536/023.100; 536/024.500
 NCLM: 435/006.000
 NCLM: 435/091.100; 435/375.000; 536/023.100; 536/024.500
 IC [71]
 ICM: C07H021-04
 ICS: C120001-68; C12N015-63
 EXF 514/44; 536/23.1; 536/24.3; 536/24.5; 435/6; 435/91.1; 435/325; 435/366;
 435/375
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 39 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
 AN 2002264120 EMBASE
 TI Lymphotoxin- β receptor immune
 AU interaction promotes tumor growth by inducing angiogenesis.
 Heindrich I.; Stoelcker B.; Stopfer P.; Muller P.; Cernatani G.; Guba M.;
 Steinhauser M.; Nedopasov S.A.; Pfeiffer K.; Mannel D.N.
 D.N. Mannel, Department of Pathology, University of Regensburg,
 F.-J. Strauss-Allee 11, D-93042 Regensburg, Germany.
 Daniela.maenne@klinik.uni-regensburg.de
 SO Cancer Research, (15 Jul 2002) 62/14 (4034-4040).
 Refs: 35
 ISSN: 0008-5472 CODEN: CREAB8
 CY United States
 DT Journal Article
 FS 016 Cancer
 PS 026 Immunology, Serology and Transplantation
 LA English
 SL English

L8 ANSWER 24 OF 39 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:338564 CAPLUS
 DN 134:348630
 TI New members of the TRAF (tumor necrosis factor receptor-associated factor)
 IN protein family with possible therapeutic uses
 PA Zapata, Juan M.; Reed, John C.
 SO The Burnham Institute, USA
 SO PCT Int. Appl., 156 pp.
 SO CODEN: PIXXD2
 DT Patent
 LA English
 LN.CNT 1
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032696	A2	20010510	WO 2000-US30533	20001103
WO 2001032696	A3	20020117		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DR, DK, DK, DE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LA, LG, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, SV, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BZ, BY, CG, CZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AT, BE, CH, CY,				

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1228088
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AU, TR
 PRAI US 1999-434784 A2 19991105
 WO 2000-US30533 W 20001103

L8 ANSWER 25 OF 39 USPATFILL
 AN 2001:231143 USPATFILL
 TI Arrays for identifying agents which mimic or inhibit the activity of
 IN interferons
 Silverman, Robert H., Beachwood, OH, United States
 Williams, Bryan R. G., Cleveland, OH, United States
 Der, Sandy, Cleveland, OH, United States
 The Cleveland Clinic Foundation, Cleveland, OH, United States (U.S. Corporation)
 PA
 PI US 631396 B1 20011218
 AI US 1999-405438 19990923 (9)
 PRAI US 1998-101497P 19980923 (60)
 DT Utility
 FS GRANTED
 LN.CNT 9639
 INCL INCLM: 435/006.000
 INCLM: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
 NCLM: 435/006.000
 NCLM: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
 IC [71]
 ICM: C120001-68
 ICS: C120001-36; C07H021-04
 EXF 435/6; 435/287.2; 536/23.1; 536/24.31; 536/23.52
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 26 OF 39 USPATFILL
 AN 2001:196600 USPATFILL
 TI Lymphotoxin- α - β complexes and anti-lymphotoxin- β receptor
 AU antibodies as anti-tumor agents
 IN Browning, Jeffrey L., 32 Milton Rd., Brookline, MA, United States 02146
 Meier, Werner, 31 Bedford St., Burlington, MA, United States 01803
 Benjamin, Christopher D., 2 Oak Hill La., Beverly, MA, United States 01915
 PI US 6312691 B1 20011106
 AI US 1998-875560 19980605 (8)
 WO 1996-US1386 19960126
 19980605 PCT 371 date
 19980605 PCT 102(e) date

DT Utility
 FS GRANTED
 LN.CNT 2254
 INCL INCLM: 424/143.100
 INCLM: 424/130.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;
 530/388.750; 530/388.800; 530/388.850
 NCLM: 424/143.100
 NCLM: 424/130.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;
 530/388.750; 530/388.800; 530/388.850
 IC [71]
 ICM: A61K039-395
 EXF 424/130.1; 424/143.1; 424/144.1; 424/809; 530/388.22; 530/388.7;
 530/388.75; 530/388.8; 530/388.85
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 27 OF 39 USPATFILL
 AN 2001:75530 USPATFILL
 TI Fas ligand-like protein, its production and use

IN Mishi, Kazunori, Ibaraki, Japan
Hikichi, Yukiko, Ibaraki, Japan
Shitani, Yasushi, Ibaraki, Japan
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI WO 6255878 B1 20010522
AI WO 9803668 19980129 19970904 (8)
US 1997-913014 19970717
WO 1997-0P2480 19970904 PCT 371 date
19970904
PRAI JP 1996-191204 19960719 PCT 102(e) date
JP 1996-211695 19960809
JP 1997-19330 19970131
DT Utility
FS Granted
LN.CNT 4854
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K001-00
EXP 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 28 OF 39 USPTFULL
L8 2001:44016 USPTFULL
TI Proteins capable of regulating NF-kappa.B JNK and apoptosis pathways
IN and methods of using the same
Chaudhary, Preet M., Dallas, TX, United States
Hood, Leroy, Seattle, WA, United States
PA University of Washington/Stowers Institute for Medical Research, United States (U.S. corporation)
PI US 6207458 B1 20010327
AI US 1998-74044 19980507 (9)
DT Utility
FS Granted
LN.CNT 1982
INCL INCLM: 435/503.000
INCLM: 435/004.000; 435/007.100; 435/007.720; 435/018.000; 435/023.000;
NCL 435/040.500; 435/040.510; 435/040.520
NCLM: 435/006.000
NCLM: 435/004.000; 435/007.100; 435/007.720; 435/018.000; 435/023.000;
IC 435/040.500; 435/040.510; 435/040.520
[7]
ICM: C12Q001-37
ICS: C120001-00; G01N033-567; G01N033-18; G01N033-53
EXP 435/503; 435/4; 435/7.1; 435/7.72; 435/18; 435/23; 435/40.5; 435/40.51;
435/40.52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 29 OF 39 CAPLUS COPYRIGHT 2003 ACS
L8 2001:544229 CAPLUS
AN 2001:544229 CAPLUS
DN 135:313303
TI Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors
Wang, Weiguang; Marsh, Sharon; Cassidy, James; McLeod, Howard L.
AU Department of Medicine and Therapeutics, Institute of Medical Sciences,
CS University of Aberdeen, Aberdeen, AB25 2ZD, UK
SO Cancer Research (2001) 6(14): 5505-5510
CODEN: CREB48; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
RE.CNT 21
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 30 OF 39 USPTFULL
AN 2000:168142 USPTFULL
TI Proteins capable of regulating NF-kappa.B, JNK and apoptosis pathways
IN and methods of using the same
Chaudhary, Preet M., Dallas, TX, United States
Hood, Leroy, Seattle, WA, United States
PA University of Washington, Seattle, WA, United States (U.S. corporation)
PI US 6160095 20001212
AI US 1999-382155 19990824 (9)
PRAI Division of Ser. No. US 1998-74044, filed on 7 May 1998
DT Utility
FS Granted
LN.CNT 2638
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K014-435
ICS: C07K014-47
EXP 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 31 OF 39 USPTFULL
L8 2000:146513 USPTFULL
AN 2000:146513 USPTFULL
TI Ligand for herpes simplex virus entry mediator and methods of use
IN Ware, Carl E., Solana Beach, CA, United States
PA La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States (U.S. corporation)
PI US 6140467 20001031
AI US 1997-898234 19970730 (8)
PRAI US 1997-51964P 19970707 (60)
DT Utility
FS Granted
LN.CNT 1522
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K014-47
EXP 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 32 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
L8 2000:345160 BIOSIS
AN 2000:345160 BIOSIS
DN PREV200000345160
TI The lymphotoxin-beta receptor is necessary
and sufficient for LIGHT-mediated apoptosis of tumor cells.
AU Rooney, Isabelle A.; Butrovich, Kris D.; Glass, Allison A.; Borboroglu, Stephen; Benedict, Chris A.; Whitbeck, J. Charles; Cohen, Gary H.; Eisenberg, Roselyn J.; Ware, Carl F. (1)
CS (1) Division of Molecular Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Dr., San Diego, CA, 92121 USA
SO Journal of Biological Chemistry, (May 12, 2000) Vol. 275, No. 19, pp. 14307-14315, print.
ISSN: 0021-9258.
DT Article
LA English
SL English
L8 ANSWER 33 OF 39 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 2000237999 EMBASE
TI Molecular cloning and characterization of a mouse homolog of human TNFSF14, a member of the TNF superfamily.
AU Misaava K.; Nosaka T.; Kojima T.; Hirai M.; Kitamura T.
CS Dr. T. Kitamura, Department of Hematopoietic Factors, Institute of Medical

L8 ANSWER 38 OF 39 MEDLINE
 AN 1998411370 MEDLINE
 DN 98411370 PubMed ID: 9739048
 TI LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer.
 AU Zhai Y; Guo R; Hsu T L; Yu G L; Ni J; Kwon B S; Jiang G W; Lu J; Tan J; Ugurel M; Carter K; Rojars L; Zhu F; Lincoln C; Endress G; Xing L; Wang S; Oh K O; Gentz R; Ruben S; Lippman M E; Hsieh S L; Yang D
 NC CAS1008 (NCI)
 SO HUMAN GENOME SCIENCES, INC., ROCKVILLE, MARYLAND 20850, USA.
 CS JOURNAL OF CLINICAL INVESTIGATION, (1998 Sep 15) 102 (6) 1142-51.
 SO JOURNAL code: 7802877. ISSN: 0021-9738.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 ED Entered STN: 19981021
 EM 199810
 ED Last Updated on STN: 19981021
 ED Entered Medline: 19981013

L8 ANSWER 39 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 AN 1996:351516 BIOSIS
 DN PREV19969073872
 TI LT-beta-R interacts with multiple TRAFs: Signaling specificity in the activation of NF-kappa-B.
 AU Force, Walker R. (1); Williams-Abbott, Laura (1); Mostafaei, George; Keff, Ellice; Nakano, Hiroyasu; Ware, Carl F. (1)
 CS (1) Biomed. Sci., Univ. Calif., Riverside, CA USA
 SO European Cytokine Network, (1996) Vol. 7, No. 2, pp. 207.
 SO Meeting Info.: 6th International Tumor Necrosis Factor Congress Rhodes, Greece May 8-12, 1996
 ISSN: 1148-5493.
 DT Conference
 LA English

=> d his
 (FILE 'HOME' ENTERED AT 12:32:53 ON 11 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONSCIT, EMBASE, CAPLUS, USPATFULL' ENTERED AT 12:33:20 ON 11 FEB 2003
 L1 136 S LYMPHOTOXIN (A) BETA (A) RECEPTOR AND ANTIBODY
 L2 42 S L1 AND INTERFERON
 L3 34 DUP REM L2 (8 DUPLICATES REMOVED)
 L4 541 S LYMPHOTOXIN (A) BETA (A) RECEPTOR
 L5 66 S L4 AND PROMOT?
 L6 43 DUP REM L5 (23 DUPLICATES REMOVED)
 L7 48 S L4 AND CANCER
 L8 39 DUP REM L7 (9 DUPLICATES REMOVED)

=> 8 Browning/in
 'IN' IS NOT A VALID FIELD CODE
 'IN' IS NOT A VALID FIELD CODE
 'IN' IS NOT A VALID FIELD CODE
 'IN' IS NOT A VALID FIELD CODE
 L9 0 BROWNING/IN

=> 8 Browning in
 L10 18038 BROWNING IN
 L11 13 L10 AND L4

=> dup rem 111
 PROCESSING COMPLETED FOR L11
 L12 13 DUP REM L11 (0 DUPLICATES REMOVED)
 => d 1-13

L12 ANSWER 1 OF 13 USPATFULL
 AN 2002:34331 USPATFULL
 TI Soluble lymphotoxin beta receptor and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for treatment
 AU Browning, Jeffrey L., Brookline, MA, UNITED STATES
 AU Hochman, Paula S., Newton, MA, UNITED STATES
 AU Reinert, Paul D., Millis, MA, UNITED STATES
 AU Mackay, Fabienne, Vauluse, AUSTRALIA
 PI US 2002197254 A1 20021226
 AI US 2001-3211 A1 20011031 (10)
 RLI Continuation of Ser. No. US 1999-299139, filed on 23 Apr 1999, PENDING
 PRAI WO 1997-US19436 19971024
 US 1996-29060P 19961025 (60)
 DT Utility
 FS APPLICATION

LN.CNT 2115
 INCL INCLM: 424/143.100
 INCL INCLM: 514/012.000
 NCL INCLM: 424/143.100
 NCLM: 514/012.000
 IC (7)
 ICM: A61K039-395
 ICS: A61K038-17
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 13 USPATFULL
 AN 2002:272468 USPATFULL
 TI Tumor necrosis factor receptors galpha & gbeta
 AU Gentz, Reiner L., Rockville, MD, UNITED STATES
 AU Ebner, Reinhard, Galtersburg, MD, UNITED STATES
 AU Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 AU Ruben, Steven M., Olney, MD, UNITED STATES
 AU Ni, Jian, Germantown, MD, UNITED STATES
 AU Feng, Ping, Galtersburg, MD, UNITED STATES
 AU Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
 PI US 2002150583 A1 20021017
 AI US 2001-895727 A1 20010824 (9)
 RLI Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 May 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING
 PRAI US 2001-303224P 20010706 (60)
 US 2000-25231P 20001121 (60)
 US 2000-227598P 20000825 (60)
 US 1999-168235P 19991201 (60)
 US 1999-146371P 19990802 (60)
 US 1999-131964P 19990430 (60)
 US 1998-131270P 19990427 (60)
 US 1998-124092P 19990312 (60)
 US 1998-121774P 19990304 (60)
 US 1997-35496P 19970114 (60)
 DT Utility
 FS APPLICATION

LN.CNT 12989
 INCL INCLM: 424/178.100
 INCL INCLM: 530/389.100

NCL NCLM: 424/178.100
NCLS: 530/389.100
[7]
ICM: A61K039-395
ICS: C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 13 USPTAFULL
AN 2002:171619 USPTAFULL
TI Anti-Lymphotoxin-beta receptor antibodies
as anti-tumor agents
IN Browning, Jeffrey L., Brookline, MA, UNITED STATES
Meier, Werner, Burlington, MA, UNITED STATES
Benjamin, Christopher D., Beverly, MA, UNITED STATES
PI US 2002090366 A1 20020711
AI US 2001-931402 A1 20010816 (9)
RLI Division of Ser. No. US 1998-875560, filed on 5 Jun 1998, PATENTED A 371 of International Ser. No. WO 1996-US1386, filed on 26 Jan 1996, UNKNOWN Continuation-in-part of Ser. No. US 1995-378968, filed on 26 Jan 1995, PENDING

DT Utility
FS APPLICATION
LN CNT 1764
INCL INCLM: 424/094.100
INCLS: 424/178.100
NCLM: 424/094.100
NCLS: 424/178.100
[7]
IC ICM: A61K039-395
ICS: A61K039-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 13 USPTAFULL
AN 2002:157048 USPTAFULL
TI APOPTOSIS INDUCING MOLECULE II AND METHODS OF USE
IN EBNER, REINHARD, GAITHERSBURG, MD, UNITED STATES
YU, GUO-LIANG, BERKELEY, CA, UNITED STATES
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES
ZHANG, JUN, BETHESDA, MD, UNITED STATES
ULIRICH, STEPHEN, ROCKVILLE, MD, UNITED STATES
ZHAI, YIFAN, GAITHERSBURG, MD, UNITED STATES
PA Human Genome Sciences (U.S. corporation)
PI US 2002081647 A1 20020627
US 6495520 B2 20021217
AI 19990319 (9)
US 1999-252656 A1 19990319 (9)
RLI Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998, PENDING Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-822953, filed on 21 Mar 1997, ABANDONED

PRAI US 1998-75409P 19980220 (60)
US 1998-13923P 19960322 (60)
US 1996-30157P 19961031 (60)
DT Utility
FS APPLICATION
LN CNT 6195
INCL INCLM: 435/069.100
INCLS: 530/350.000; 530/399.000; 514/012.000; 536/023.500
NCLM: 514/012.000
NCLS: 530/300.000; 530/324.000; 530/350.000
[7]
IC ICM: A61K038-18
ICS: C12P021-06; C07H021-04; C07K014-00; G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 13 USPTAFULL

AN 2002:126357 USPTAFULL
TI APOPTOSIS INDUCING MOLECULE II
IN EBNER, REINHARD, GAITHERSBURG, MD, UNITED STATES
YU, GUO-LIANG, DARNESTOWN, MD, UNITED STATES
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES
ULIRICH, STEPHEN, ROCKVILLE, MD, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2002064869 A1 20020530
US 6479254 B2 20021112
AI US 1998-27287 A1 19980220 (9)
RLI Continuation-in-part of Ser. No. US 1997-822953, filed on 21 Mar 1997, ABANDONED

PRAI US 1996-30157P 19961031 (60)
US 1996-13923P 19960322 (60)
DT Utility
FS APPLICATION
LN CNT 4242
INCL INCLM: 435/320.100
INCLS: 435/069.100; 435/325.000; 536/023.500
NCLM: 435/069.100
NCLS: 435/069.700; 435/320.100; 435/325.000; 530/324.000; 536/023.400; 536/023.500; 536/024.100; 930/144.000
[7]
IC ICM: C12N015-63
ICS: C07H021-04; C12N015-00; C12N015-74; C12N005-06; C12N015-70; C12N015-09
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 6 OF 13 USPTAFULL
AN 2002:72443 USPTAFULL
TI Method for the high level expression of active Lymphotoxin-beta receptor immunoglobulin chimeric proteins and their purification
IN Browning, Jeffrey, Brookline, MA, UNITED STATES
Mlakowski, Konrad, North Reading, MA, UNITED STATES
Meier, Werner, Burlington, MA, UNITED STATES
PI US 2002039580 A1 20020404
AI US 2001-767370 A1 20010123 (9)
RLI Continuation of Ser. No. WO 1999-US29873, filed on 16 Dec 1999, UNKNOWN

PRAI US 1998-112752P 19981217 (60)
DT Utility
FS APPLICATION
LN CNT 1163
INCL INCLM: 424/178.100
INCLS: 530/389.100; 435/069.700; 435/328.000; 530/351.000
NCLM: 424/178.100
NCLS: 530/389.100; 435/069.700; 435/328.000; 530/351.000
[7]
IC ICM: A61K039-395
ICS: C12P021-04; C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 7 OF 13 USPTAFULL
AN 2002:26858 USPTAFULL
TI Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
IN Remmett, Paul, Mills, MA, UNITED STATES
PI US 2002015703 A1 20020207
AI US 2001-905610 A1 20010713 (9)
WO 2000-US1044 20000014
PRAI US 1999-116168P 19990115 (60)
DT Utility
FS APPLICATION
LN CNT 1303
INCL INCLM: 424/143.100

NCL NCLM: 424/143.100
 IC [7]
 ICM: A61K039-395
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 8 OF 13 USPTFULL
 AN 2002:8587 USPTFULL
 TI Multivalent antibodies and uses thereof
 IN Miller, Kathy L., San Francisco, CA, UNITED STATES
 PIA Preata, Leonard G., San Francisco, CA, UNITED STATES
 PI GENENTECH, INC. (U.S. corporation)
 PI US 2002004587 U.S. 20020110
 AI US 2001-813341 AI 20010320 (9)
 PRAI US 2000-195819P 20000411 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4913
 INCL INCLM: 530/388.800
 INCLM: 536/023.500; 435/325.000; 435/334.000; 424/143.100
 NCL NCLM: 530/388.800
 NCLM: 536/023.500; 435/325.000; 435/334.000; 424/143.100
 IC [7]
 ICM: C07K016-28
 ICS: A61K039-395; C07H021-04; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 13 USPTFULL
 AN 2002:3612 USPTFULL
 TI Reversal of viral-induced systemic shock and respiratory distress by
 IN blockade of the lymphotoxin beta pathway
 Browning, Jeffrey, Brookline, MA, UNITED STATES
 PIA Pugliese, Maryann, Alexandria, VA, UNITED STATES
 PI Ahmed, Rafi, Atlanta, GA, UNITED STATES
 PI US 2002001585 AI 20020103
 AI US 2001-829031 AI 20010409 (9)
 RLI Continuation of Ser. No. WO 1999-0523477, filed on 8 Oct 1999, UNKNOWN
 PRAI US 1998-103662P 19981009 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1040
 INCL INCLM: 424/143.100
 INCLM: 424/147.100; 435/328.000; 435/334.000
 NCL INCLM: 424/143.100
 NCLM: 424/147.100; 435/328.000; 435/334.000
 IC [7]
 ICM: A61K039-42
 ICS: A61K039-395; C12N005-06; C12N005-16
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 10 OF 13 USPTFULL
 AN 2002:136562 USPTFULL
 TI Soluble lymphotoxin-.beta. receptors as
 IN therapeutic agents for the treatment of immunological disease
 Browning, Jeffrey L., Brookline, MA, United States
 PIA Benjamin, Christopher D., Beverly, MA, United States
 PI Hochman, Paula S., Newton, MA, United States
 PI Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
 PI US 6403087 BI 20020611
 WO 9703687 19970206
 AI US 1998-166 19980608 (9)
 WO 1996-US12010 19960719
 RLI Continuation-in-part of Ser. No. US 1995-505606, filed on 21 Jul 1995,
 DT Utility
 Utility

FS GRANTED
 LN.CNT 1983
 INCL INCLM: 424/134.100
 INCLM: 424/134.100; 424/133.100; 514/002.000; 514/008.000; 530/387.100;
 INCLM: 530/387.300
 NCL NCLM: 424/134.100
 NCLM: 424/133.100; 514/002.000; 514/008.000; 530/387.100; 530/387.300
 IC [7]
 ICM: A61K039-395
 ICS: A61K038-16
 EXF 424/148.1; 424/144.1; 424/145.1; 424/156.1; 514/2; 514/8; 530/395;
 530/387.1; 530/388.22; 530/388.23; 530/388.73; 530/388.85; 530/389.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 11 OF 13 USPTFULL
 AN 2001:196600 USPTFULL
 TI Lymphotoxin-.alpha.-.beta. complexes and anti-lymphotoxin-.beta. receptor
 IN antibodies as anti-tumor agents
 Browning, Jeffrey L., 32 Milton Rd., Brookline, MA, United States 02146
 PI Meier, Werner, 31 Bedford St., Burlington, MA, United States 01803
 PIA Benjamin, Christopher D., 2 Oak Hill La., Beverly, MA, United States
 01915
 PI US 6312691 BI 20011106
 WO 9622788 19960801
 AI US 1998-875560 19980605 (8)
 WO 1996-US1386 19960126
 19980605 PCT 102(e) date

DT Utility
 FS GRANTED
 LN.CNT 2254
 INCL INCLM: 424/143.100
 INCLM: 424/130.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;
 INCLM: 424/130.100; 530/388.750; 530/388.800; 530/388.850
 NCL NCLM: 424/143.100
 NCLM: 424/143.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;
 NCLM: 424/130.100; 530/388.750; 530/388.800; 530/388.850
 IC [7]
 ICM: A61K039-395
 EXF 424/130.1; 424/143.1; 424/144.1; 424/809; 530/388.22; 530/388.7;
 530/388.75; 530/388.8; 530/388.85
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 12 OF 13 USPTFULL
 AN 2000:146513 USPTFULL
 TI Ligand for herpes simplex virus entry mediator and methods of use
 IN Ware, Carl E., Solana Beach, CA, United States
 PIA La Jolla Institute for Allergy and Immunology, La Jolla, CA, United
 States (U.S. corporation)
 PI US 6140467 20001031
 AI US 1997-898234 19970730 (8)
 PRAI US 1997-51964P 19970707 (60)
 DT Utility
 FS Granted
 LN.CNT 1522
 INCL INCLM: 530/350.000
 INCLM: 530/350.000
 NCL NCLM: 530/350.000
 IC [7]
 ICM: C07K014-47
 EXF 530/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 13 OF 13 USPTFULL
 AN 1999:81543 USPTFULL
 TI Soluble lymphotoxin-.beta. receptors and

anti-lymphotoxin receptor and ligand antibodies as therapeutic agents
for the treatment of immunological disease
IN Browning, Jeffrey L., Brookline, MA, United States
Benjamin, Christopher D., Beverly, MA, United States
Hochman, Paula S., Brookline, MA, United States
PA Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
FI US 5925351 19990720
AI US 1995-505606 19950721 (8)
DT Utility
FS Granted
LN.CNT 1968
INCL INCLM: 424/143.100
INCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000;
530/395.000; 530/387.100; 530/388.220; 530/388.230; 530/388.730;
530/388.850; 530/389.200
NCL NCLM: 424/143.100
NCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000;
530/387.100; 530/388.220; 530/388.230; 530/388.730; 530/388.850;
530/389.200; 530/395.000
IC [6]
ICM: A61K039-395
ICS: A61K038-16; C07K016-00; C07K016-28
EXP 514/218; 530/395; 530/387.1; 530/388.22; 530/388.23; 530/388.73;
530/388.85; 530/389.2; 424/143.1; 424/144.1; 424/145.1; 424/156.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

--Logging off of STN--

Executing the logoff script...

=> LOG Y
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
168.21 168.42
STN INTERNATIONAL LOGOFF AT 12:55:25 ON 11 FEB 2003